



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/12/20
(87) Date publication PCT/PCT Publication Date: 2019/06/27
(85) Entrée phase nationale/National Entry: 2020/06/15
(86) N° demande PCT/PCT Application No.: US 2018/066667
(87) N° publication PCT/PCT Publication No.: 2019/126424
(30) Priorité/Priority: 2017/12/22 (US62/609,834)

(51) Cl.Int./Int.Cl. *C07D 471/04* (2006.01),
A61K 31/444 (2006.01)


(71) Demandeur/Applicant:
CHEMOCENTRYX, INC., US

(72) Inventeurs/Inventors:
FAN, PINGCHEN, US;
LANGE, CHRISTOPHER W., US;
MALATHONG, VIENGGHAM, US;
MALI, VENKAT REDDY, US;
PUNNA, SREENIVAS, US;
TANAKA, HIROKO, US;
ZENG, YIBIN, US;
ZHANG, PENGLIE, US

(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : COMPOSES CYCLIQUES CONDENSES 6,5 A SUBSTITUTION DIARYLE, UTILISES EN TANT QU'INHIBITEURS DU C5AR

(54) Title: DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5AR INHIBITORS



(57) Abrégé/Abstract:

The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 June 2019 (27.06.2019)




(10) International Publication Number
WO 2019/126424 A1

- (51) **International Patent Classification:**
C07D 231/56 (2006.01) C07D 471/04 (2006.01)
- (21) **International Application Number:**
PCT/US2018/066667
- (22) **International Filing Date:**
20 December 2018 (20.12.2018)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/609,834 22 December 2017 (22.12.2017) US
- (71) **Applicant: CHEMOCENTRYX, INC.** [US/US]; 850 Maude Avenue, Mountain View, California 94043 (US).
- (72) **Inventors: FAN, Pingchen;** 2157 Kalenda Commons, Fremont, California 94539 (US). **LANGE, Christopher W.;** 6818 Cutting Boulevard, El Cerrito, California 94530 (US). **MALATHONG, Viengkham;** 1221 Judson Street, Belmont, California 94002 (US). **MALI, Venkat Reddy;** 20200 Lucille Avenue, Apt. 4, Cupertino, California 95014 (US). **PUNNA, Sreenivas;** 938 Fontana Terrace, Sunnyvale, California 94085 (US). **TANAKA, Hiroko;** 600 Rainbow Drive, #148, Mountain View, California 94041 (US). **ZENG, Yibin;** 917 Aruba Lane, Foster City, California 94404 (US). **ZHANG, Penglie;** 1036 Jamaica Street, Foster City, California 94404 (US).
- (74) **Agent: KEZER, William B.** et al.; One Financial Center, Boston, Massachusetts 02111 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS



(I)

(57) **Abstract:** The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.



WO 2019/126424 A1

DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS**CROSS-REFERENCES TO RELATED APPLICATIONS**

[0001] This application is an application claiming benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/609,834 filed December 22, 2017, which is herein incorporated by reference in its entirety.

**STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER
FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT**

[0002] NOT APPLICABLE

10 **REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER
PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK**

[0003] NOT APPLICABLE

BACKGROUND OF THE INVENTION

[0004] The complement system plays a central role in the clearance of immune complexes and in immune responses to infectious agents, foreign antigens, virus infected cells and tumor cells. Inappropriate or excessive activation of the complement system can lead to harmful, and even potentially life-threatening consequences due to severe inflammation and resulting tissue destruction. These consequences are clinically manifested in various disorders including septic shock; myocardial, as well as, intestinal ischemia/reperfusion injury; graft rejection; organ failure; nephritis; pathological inflammation; and autoimmune diseases.

[0005] The complement system is composed of a group of proteins that are normally present in the serum in an inactive state. Activation of the complement system encompasses mainly three distinct pathways, *i.e.*, the classical, the alternative, and the lectin pathway (V. M. Holers, *In Clinical Immunology: Principles and Practice*, ed. R. R. Rich, Mosby Press; 1996, 363-391): 1) The classical pathway is a calcium/magnesium-dependent cascade, which is normally activated by the formation of antigen-antibody complexes. It can also be activated in an antibody-independent manner by the binding of C-reactive protein, complexed with ligand, and by many

pathogens including gram-negative bacteria. 2) The alternative pathway is a magnesium-dependent cascade which is activated by deposition and activation of C3 on certain susceptible surfaces (e.g. cell wall polysaccharides of yeast and bacteria, and certain biopolymer materials). 3) The lectin pathway involves the initial binding of mannose-binding lectin and the subsequent
5 activation of C2 and C4, which are common to the classical pathway (Matsushita, M. *et al.*, *J. Exp. Med.* 176: 1497-1502 (1992); Suankratay, C. *et al.*, *J. Immunol.* 160: 3006-3013 (1998)).

[0006] The activation of the complement pathway generates biologically active fragments of complement proteins, e.g. C3a, C4a and C5a anaphylatoxins and C5b-9 membrane attack complexes (MAC), all which mediate inflammatory responses by affecting leukocyte
10 chemotaxis; activating macrophages, neutrophils, platelets, mast cells and endothelial cells; and increasing vascular permeability, cytolysis and tissue injury.

[0007] Complement C5a is one of the most potent proinflammatory mediators of the complement system. (The anaphylactic C5a peptide is 100 times more potent, on a molar basis, in eliciting inflammatory responses than C3a.) C5a is the activated form of C5 (190 kD,
15 molecular weight). C5a is present in human serum at approximately 80 µg/ml (Kohler, P. F. *et al.*, *J. Immunol.* 99: 1211-1216 (1967)). It is composed of two polypeptide chains, α and β, with approximate molecular weights of 115 kD and 75 kD, respectively (Tack, B. F. *et al.*, *Biochemistry* 18: 1490-1497 (1979)). Biosynthesized as a single-chain promolecule, C5 is enzymatically cleaved into a two-chain structure during processing and secretion. After
20 cleavage, the two chains are held together by at least one disulphide bond as well as noncovalent interactions (Ooi, Y. M. *et al.*, *J. Immunol.* 124: 2494-2498(1980)).

[0008] C5 is cleaved into the C5a and C5b fragments during activation of the complement pathways. The convertase enzymes responsible for C5 activation are multi-subunit complexes of C4b, C2a, and C3b for the classical pathway and of (C3b)₂, Bb, and P for the alternative pathway
25 (Goldlust, M. B. *et al.*, *J. Immunol.* 113: 998-1007 (1974); Schreiber, R. D. *et al.*, *Proc. Natl. Acad. Sci.* 75: 3948-3952 (1978)). C5 is activated by cleavage at position 74-75 (Arg-Leu) in the α-chain. After activation, the 11.2 kD, 74 amino acid peptide C5a from the amino-terminus portion of the α-chain is released. Both C5a and C3a are potent stimulators of neutrophils and monocytes (Schindler, R. *et al.*, *Blood* 76: 1631-1638 (1990); Haeffner-Cavaillon, N. *et al.*, *J.*
30 *Immunol.* 138: 794-700 (1987); Cavaillon, J. M. *et al.*, *Eur. J. Immunol.* 20: 253-257 (1990)).

[0009] In addition to its anaphylatoxic properties, C5a induces chemotactic migration of neutrophils (Ward, P. A. *et al.*, *J. Immunol.* 102: 93-99 (1969)), eosinophils (Kay, A. B. *et al.*, *Immunol.* 24: 969-976 (1973)), basophils (Lett-Brown, M. A. *et al.*, *J. Immunol.* 117: 246-252 (1976)), and monocytes (Snyderman, R. *et al.*, *Proc. Soc. Exp. Biol. Med.* 138: 387-390 (1971)).

5 Both C5a and C5b-9 activate endothelial cells to express adhesion molecules essential for sequestration of activated leukocytes, which mediate tissue inflammation and injury (Foreman, K. E. *et al.*, *J. Clin. Invest.* 94: 1147-1155 (1994); Foreman, K. E. *et al.*, *Inflammation* 20: 1-9 (1996); Rollins, S. A. *et al.*, *Transplantation* 69: 1959-1967 (2000)). C5a also mediates inflammatory reactions by causing smooth muscle contraction, increasing vascular permeability, inducing basophil and mast cell degranulation and inducing release of lysosomal proteases and oxidative free radicals (Gerard, C. *et al.*, *Ann. Rev. Immunol.* 12: 775-808 (1994)). Furthermore, C5a modulates the hepatic acute-phase gene expression and augments the overall immune response by increasing the production of TNF- α , IL-1- β , IL-6, IL-8, prostaglandins and leukotrienes (Lambris, J. D. *et al.*, *In: The Human Complement System in Health and Disease*,
10 Volanakis, J. E. ed., Marcel Dekker, New York, pp. 83-118).
15

[0010] The anaphylactic and chemotactic effects of C5a are believed to be mediated through its interaction with the C5a receptor. The human C5a receptor (C5aR) is a 52 kD membrane bound G protein-coupled receptor, and is expressed on neutrophils, monocytes, basophils, eosinophils, hepatocytes, lung smooth muscle and endothelial cells, and renal glomerular tissues (Van-Epps, D. E. *et al.*, *J. Immunol.* 132: 2862-2867 (1984); Haviland, D. L. *et al.*, *J. Immunol.* 154:1861-1869 (1995); Wetsel, R. A., *Immunol. Leff.* 44: 183-187 (1995); Buchner, R. R. *et al.*, *J. Immunol.* 155: 308-315 (1995); Chenoweth, D. E. *et al.*, *Proc. Natl. Acad. Sci.* 75: 3943-3947 (1978); Zwirner, J. *et al.*, *Mol. Immunol.* 36:877-884 (1999)). The ligand-binding site of C5aR is complex and consists of at least two physically separable binding domains. One binds the C5a amino terminus (amino acids 1-20) and disulfide-linked core (amino acids 21-61), while the second binds the C5a carboxy-terminal end (amino acids 62-74) (Wetsel, R. A., *Curr. Opin. Immunol.* 7: 48-53 (1995)).
20
25

[0011] C5a plays important roles in inflammation and tissue injury. In cardiopulmonary bypass and hemodialysis, C5a is formed as a result of activation of the alternative complement pathway when human blood makes contact with the artificial surface of the heart-lung machine
30

or kidney dialysis machine (Howard, R. J. *et al.*, *Arch. Surg.* 123: 1496-1501 (1988); Kirklin, J. K. *et al.*, *J. Cardiovasc. Surg.* 86: 845-857 (1983); Craddock, P. R. *et al.*, *N. Engl. J. Med.* 296: 769-774 (1977)). C5a causes increased capillary permeability and edema, bronchoconstriction, pulmonary vasoconstriction, leukocyte and platelet activation and infiltration to tissues, in particular the lung (Czermak, B. J. *et al.*, *J. Leukoc. Biol.* 64: 40-48 (1998)). Administration of an anti-C5a monoclonal antibody was shown to reduce cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction (Tofukuji, M. *et al.*, *J. Thorac. Cardiovasc. Surg.* 116: 1060-1068 (1998)).

[0012] C5a is also involved in acute respiratory distress syndrome (ARDS), Chronic

Obstructive Pulmonary Disorder (COPD) and multiple organ failure (MOF) (Hack, C. E. *et al.*, *Am. J. Med.* 1989; 86: 20-26; Hammerschmidt DE *et al. Lancet* 1980; 1: 947-949; Heideman M. *et al. J. Trauma* 1984; 4: 1038-1043; Marc, MM, *et al.*, *Am. J. Respir. Cell and Mol. Biol.*, 2004: 31: 216-219). C5a augments monocyte production of two important pro-inflammatory cytokines, TNF- α and IL-1. C5a has also been shown to play an important role in the development of tissue injury, and particularly pulmonary injury, in animal models of septic shock (Smedegard G *et al. Am. J. Pathol.* 1989; 135: 489-497; Markus, S., *et al.*, *FASEB Journal* (2001), 15: 568-570). In sepsis models using rats, pigs and non-human primates, anti-C5a antibodies administered to the animals before treatment with endotoxin or E. coli resulted in decreased tissue injury, as well as decreased production of IL-6 (Smedegard, G. *et al.*, *Am. J. Pathol.* 135: 489-497 (1989); Hopken, U. *et al.*, *Eur. J. Immunol.* 26: 1103-1109 (1996); Stevens, J. H. *et al.*, *J. Clin. Invest.* 77: 1812-1816 (1986)). More importantly, blockade of C5a with anti-C5a polyclonal antibodies has been shown to significantly improve survival rates in a caecal ligation/puncture model of sepsis in rats (Czermak, B.J. *et al.*, *Nat. Med.* 5: 788-792 (1999)). This model share many aspects of the clinical manifestation of sepsis in humans. (Parker, S.J. *et al.*, *Br. J. Surg.* 88: 22-30 (2001)). In the same sepsis model, anti-C5a antibodies were shown to inhibit apoptosis of thymocytes (Guo, R.F. *et al.*, *J. Clin. Invest.* 106: 1271-1280 (2000)) and prevent MOF (Huber-Lang, M. *et al.*, *J. Immunol.* 166: 1193-1199 (2001)). Anti-C5a antibodies were also protective in a cobra venom factor model of lung injury in rats, and in immune complex-induced lung injury (Mulligan, M. S. *et al. J. Clin. Invest.* 98: 503-512 (1996)). The importance of C5a in immune complex-mediated lung injury was later confirmed in mice (Bozic, C. R. *et al.*, *Science* 26: 1103-1109 (1996)).

[0013] C5a is found to be a major mediator in myocardial ischemia-reperfusion injury. Complement depletion reduced myocardial infarct size in mice (Weisman, H. F. *et al.*, *Science* 249: 146-151 (1990)), and treatment with anti-C5a antibodies reduced injury in a rat model of hindlimb ischemia-reperfusion (Bless, N. M. *et al.*, *Am. J. Physiol.* 276: L57-L63 (1999)).

5 Reperfusion injury during myocardial infarction was also markedly reduced in pigs that were retreated with a monoclonal anti-C5a IgG (Amsterdam, E. A. *et al.*, *Am. J. Physiol.* 268:H448-H457 (1995)). A recombinant human C5aR antagonist reduces infarct size in a porcine model of surgical revascularization (Riley, R. D. *et al.*, *J. Thorac. Cardiovasc. Surg.* 120: 350-358 (2000)).

10 [0014] C5a driven neutrophils also contribute to many bullous diseases (e.g., bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus). These are chronic and recurring inflammatory disorders clinically characterized by sterile blisters that appear in the sub-epidermal space of the skin and mucosa. While autoantibodies to keratinocytes located at the cutaneous basement membranes are believed to underlie the detachment of epidermal basal
15 keratinocytes from the underlying basement membrane, blisters are also characterized by accumulation of neutrophils in both the upper dermal layers and within the blister cavities. In experimental models a reduction of neutrophils or absence of complement (total or C5-selective) can inhibit formation of sub-epidermal blisters, even in the presence of high auto-antibody titers.

[0015] Complement levels are elevated in patients with rheumatoid arthritis (Jose, P. J. *et al.*,
20 *Ann. Rheum. Dis.* 49: 747-752 (1990); Grant, E.P., *et al.*, *J. of Exp. Med.*, 196(11): 1461-1471, (2002)), lupus nephritis (Bao, L., *et al.*, *Eur. J. of Immunol.*, 35(8), 2496-2506, (2005)) and systemic lupus erythematosus (SLE) (Porcel, J. M. *et al.*, *Clin. Immunol. Immunopathol.* 74: 283-288 (1995)). C5a levels correlate with the severity of the disease state. Collagen-induced arthritis in mice and rats resembles the rheumatoid arthritic disease in human. Mice deficient in
25 the C5a receptor demonstrated a complete protection from arthritis induced by injection of monoclonal anti-collagen Abs (Banda, N.K., *et al.*, *J. of Immunol.*, 2003, 171: 2109-2115). Therefore, inhibition of C5a and/or C5a receptor (C5aR) could be useful in treating these chronic diseases.

[0016] The complement system is believed to be activated in patients with inflammatory bowel
30 disease (IBD) and is thought to play a role in the disease pathogenesis. Activated complement

products were found at the luminal face of surface epithelial cells, as well as in the muscularis mucosa and submucosal blood vessels in IBD patients (Woodruff, T.M., *et al.*, *J of Immunol.*, 2003, 171: 5514-5520).

5 [0017] C5aR expression is upregulated on reactive astrocytes, microglia, and endothelial cells in an inflamed human central nervous system (Gasque, P. *et al.*, *Am. J. Pathol.* 150: 31-41 (1997)). C5a might be involved in neurodegenerative diseases, such as Alzheimer disease (Mukherjee, P. *et al.*, *J. Neuroimmunol.* 105: 124-130 (2000); O'Barr, S. *et al.*, *J. Neuroimmunol.* (2000) 105: 87-94; Farkas, I., *et al. J. Immunol.* (2003) 170:5764-5771), Parkinson's disease, Pick disease and transmissible spongiform encephalopathies. Activation of neuronal C5aR may
10 induce apoptosis (Farkas I *et al. J. Physiol.* 1998; 507: 679-687). Therefore, inhibition of C5a and/or C5aR could also be useful in treating neurodegenerative diseases.

[0018] There is some evidence that C5a production worsens inflammation associated with atopic dermatitis (Neuber, K., *et al.*, *Immunology* 73:83-87, (1991)), and chronic urticaria (Kaplan, A.P., *J. Allergy Clin. Immunol.* 114; 465-474, (2004).

15 [0019] Psoriasis is now known to be a T cell-mediated disease (Gottlieb, E. L. *et al.*, *Nat. Med.* 1: 442-447 (1995)). However, neutrophils and mast cells may also be involved in the pathogenesis of the disease (Terui, T. *et al.*, *Exp. Dermatol.* 9: 1-10; 2000); Werfel, T. *et al.*, *Arch. Dermatol. Res.* 289: 83-86 (1997)). Neutrophil accumulation under the stratum corneum is observed in the highly inflamed areas of psoriatic plaques, and psoriatic lesion (scale) extracts
20 contain highly elevated levels of C5a and exhibit potent chemotactic activity towards neutrophils, an effect that can be inhibited by addition of a C5a antibody. T cells and neutrophils are chemo-attracted by C5a (Nataf, S. *et al.*, *J. Immunol.* 162: 4018-4023 (1999); Tsuji, R. F. *et al.*, *J. Immunol.* 165: 1588-1598 (2000); Cavaillon, J. M. *et al.*, *Eur. J. Immunol.* 20: 253-257 (1990)). Additionally expression of C5aR has been demonstrated in plasmacytoid dendritic cells
25 (pDC) isolated from lesions of cutaneous lupus erythematosus and these cells were shown to display chemotactic behavior towards C5a, suggesting that blockade of C5aR on pDC might be efficacious in reducing pDC infiltration into inflamed skin in both SLE and psoriasis. Therefore C5a could be an important therapeutic target for treatment of psoriasis.

[0020] Immunoglobulin G-containing immune complexes (IC) contribute to the pathophysiology in a number of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren's disease, Goodpasture's syndrome, and hypersensitivity pneumonitis (Madaio, M. P., *Semin. Nephrol.* 19: 48-56 (1999); Korganow, A. S. *et al.*, *Immunity* 10: 451-459 (1999); Bolten, W. K., *Kidney Int.* 50: 1754-1760 (1996); Ando, M. *et al.*, *Curr. Opin. Pulm. Med.* 3: 391-399 (1997)). These diseases are highly heterogeneous and generally affect one or more of the following organs: skin, blood vessels, joints, kidneys, heart, lungs, nervous system and liver (including cirrhosis and liver fibrosis). The classical animal model for the inflammatory response in these IC diseases is the Arthus reaction, which features the infiltration of polymorphonuclear cells, hemorrhage, and plasma exudation (Arthus, M., *C.R. Soc. Biol.* 55: 817-824 (1903)). Recent studies show that C5aR deficient mice are protected from tissue injury induced by IC (Kohl, J. *et al.*, *Mol. Immunol.* 36: 893-903 (1999); Baumann, U. *et al.*, *J. Immunol.* 164: 1065-1070 (2000)). The results are consistent with the observation that a small peptidic anti-C5aR antagonist inhibits the inflammatory response caused by IC deposition (Strachan, A. J. *et al.*, *J. Immunol.* 164: 6560-6565 (2000)). Together with its receptor, C5a plays an important role in the pathogenesis of IC diseases. Inhibitors of C5a and C5aR could be useful to treat these diseases.

Descripton of Related Art:


[0021] Non-peptide based C5a receptor antagonist have been reported as being effective for treating endotoxic shock in rats (Stracham, A.J., *et al.*, *J. of Immunol.* (2000), 164(12): 6560-6565); and for treating IBD in a rat model (Woodruff, T.M., *et al.*, *J of Immunol.*, 2003, 171: 5514-5520). Non-peptide based C5a receptor modulators also have been described in the patent literature by Neurogen Corporation, (*e.g.*, WO2004/043925, WO2004/018460, WO2005/007087, WO03/082826, WO03/08828, WO02/49993, WO03/084524); Dompe S.P.A. (WO02/029187); The University of Queensland (WO2004/100975); and ChemoCentryx (WO2010/075257).

[0022] There is considerable experimental evidence in the literature that implicates increased levels of C5a with a number of diseases and disorders, in particular in autoimmune and inflammatory diseases and disorders. Thus, there remains a need in the art for new small organic molecule modulators, *e.g.*, agonists, preferably antagonists, partial agonists, of the C5a receptor

(C5aR) that are useful for inhibiting pathogenic events, *e.g.*, chemotaxis, associated with increased levels anaphylatoxin activity. The present invention fulfills this and other needs.

BRIEF SUMMARY OF THE INVENTION

[0023] In one aspect, the present invention provide compounds of Formula (I):



5

or a pharmaceutically acceptable salt thereof, wherein the symbols, letters and subscripts n, m, a, b, e, X¹, R¹, R^{2a}, R^{2b}, R³, R⁴ and R⁵ have the meanings provided in the description below.

[0024] In addition to the compounds provided herein, the present invention further provides pharmaceutical compositions containing one or more of these compounds, as well as methods for the use of these compounds in therapeutic methods, primarily to treat diseases associated C5a signaling activity.

[0025] In yet another aspect, the present invention provides methods of diagnosing disease in an individual. In these methods, the compounds provided herein are administered in labeled form to a subject, followed by diagnostic imaging to determine the presence or absence of C5aR and/or the localization of cells expressing a C5aR receptor. In a related aspect, a method of diagnosing disease is carried out by contacting a tissue or blood sample with a labeled compound as provided herein and determining the presence, absence, amount, or localization of C5aR in the sample.

15

BRIEF DESCRIPTION OF THE DRAWINGS

20 [0026] NOT APPLICABLE

DETAILED DESCRIPTION OF THE INVENTION

I. Abbreviation and Definitions

[0027] The term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical, having the number of carbon atoms designated (*i.e.* C₁₋₈ means one to eight carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. The term "alkenyl" refers to an unsaturated alkyl group having one or more double bonds. Similarly, the term "alkynyl" refers to an unsaturated alkyl group having one or more triple bonds. Examples of such unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), isobutenyl, 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butylnyl, and the higher homologs and isomers. The term "cycloalkyl" refers to hydrocarbon rings having the indicated number of ring atoms (*e.g.*, C₃₋₆cycloalkyl) and being fully saturated or having no more than one double bond between ring vertices. "Cycloalkyl" is also meant to refer to bicyclic and polycyclic hydrocarbon rings such as, for example, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, etc. The term "heterocycloalkyl" refers to a cycloalkyl group that contain from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. The heterocycloalkyl may be a monocyclic, a bicyclic or a polycyclic ring system. Non limiting examples of heterocycloalkyl groups include pyrrolidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, dioxolane, phthalimide, piperidine, 1,4-dioxane, morpholine, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S,S-oxide, piperazine, pyran, pyridone, 3-pyrroline, thiopyran, pyrone, tetrahydrofuran, tetrahydrothiophene, quinuclidine, and the like. A heterocycloalkyl group can be attached to the remainder of the molecule through a ring carbon or a heteroatom.

[0028] The term "alkylene" by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by -CH₂CH₂CH₂CH₂-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer

carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having four or fewer carbon atoms. Similarly, "alkenylene" and "alkynylene" refer to the unsaturated forms of "alkylene" having double or triple bonds, respectively.

[0029] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. The heteroatom Si may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule. Examples include -CH₂-CH₂-O-CH₃, -CH₂-CH₂-NH-CH₃, -CH₂-CH₂-N(CH₃)-CH₃, -CH₂-S-CH₂-CH₃, -CH₂-CH₂-S(O)-CH₃, -CH₂-CH₂-S(O)₂-CH₃, -CH=CH-O-CH₃, -Si(CH₃)₃, -CH₂-CH=N-OCH₃, and -CH=CH-N(CH₃)-CH₃. Up to two heteroatoms may be consecutive, such as, for example, -CH₂-NH-OCH₃ and -CH₂-O-Si(CH₃)₃. Similarly, the terms "heteroalkenyl" and "heteroalkynyl" by itself or in combination with another term, means, unless otherwise stated, an alkenyl group or alkynyl group, respectively, that contains the stated number of carbons and having from one to three heteroatoms selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group.

[0030] The term "heteroalkylene" by itself or as part of another substituent means a divalent radical, saturated or unsaturated or polyunsaturated, derived from heteroalkyl, as exemplified by -CH₂-CH₂-S-CH₂CH₂- and -CH₂-S-CH₂-CH₂-NH-CH₂-, -O-CH₂-CH=CH-, -CH₂-CH=C(H)CH₂-O-CH₂- and -S-CH₂-C≡C-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (*e.g.*, alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).

[0031] The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively. Additionally, for dialkylamino groups, the alkyl portions can be the same or different and can also be combined to form a 3-7 membered ring with the nitrogen atom to which each is attached. Accordingly, a group represented as $-NR^aR^b$ is meant to include piperidinyl, pyrrolidinyl, morpholinyl, azetidiny and the like.

[0032] The term "hydroxyalkyl" is used in its conventional sense, and refers to branched or straight chain alkyl group substituted with at least one hydroxyl group. The hydroxyl group may be at any position in the alkyl group. For example, the term "C₁₋₄hydroxyalkyl" is meant to include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxyisopropyl, and the like.

[0033] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "C₁₋₄ haloalkyl" is mean to include trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0034] The term "aryl" means, unless otherwise stated, a polyunsaturated, typically aromatic, hydrocarbon group which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings) that contain from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl groups include phenyl, naphthyl and biphenyl, while non-limiting examples of heteroaryl groups include pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, triazinyl, quinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, benzotriazinyl, purinyl, benzimidazolyl, benzopyrazolyl, benzooxazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, pyrrolopyridyl, imidazopyridines, benzothiazolyl,

benzofuranyl, benzothienyl, indolyl, quinolyl, isoquinolyl, isothiazolyl, pyrazolyl, indazolyl, pteridinyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrrolyl, thiazolyl, furyl, thienyl and the like. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.

[0035] The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of salts derived from pharmaceutically-acceptable inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like. Salts derived from pharmaceutically-acceptable organic bases include salts of primary, secondary and tertiary amines, including substituted amines, cyclic amines, naturally-occurring amines and the like, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperadine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like

glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., et al, "Pharmaceutical Salts", *Journal of Pharmaceutical Science*, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

[0036] The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

[0037] In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

[0038] Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0039] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers, regioisomers and individual isomers (*e.g.*, separate enantiomers) are all intended to be encompassed within the scope of the present invention. The compounds of the present invention may also contain 5 unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the


compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[0040] As used herein, a wavy line, "~~~~", that intersects a single, double or triple bond in any chemical structure depicted herein, represent the point attachment of the single, double, or triple bond to the remainder of the molecule.

II. Description of the Embodiments

A. Compounds

[0041] In one aspect, the present invention provides compounds of Formula (I):



or a pharmaceutically acceptable salt thereof, wherein,

10 ring vertex a is N or C(R^{2c}), ring vertex b is N or C(R^{2d}), and ring vertex e is N or C(R^{2e}),
wherein no more than one of a, b and e is N;

X¹ is selected from the group consisting of a bond, C₁₋₈ alkylene, C(O), C(O)-C₁₋₄ alkylene,
and S(O)₂;

R¹ is selected from the group consisting of

- 15 a) 5- to 10-membered heteroaryl having from 1 to 4 heteroatoms as ring vertices selected from N, O and S;
- b) C₆₋₁₀ aryl;
- c) C₃₋₈ cycloalkyl;
- 20 d) 4- to 8-membered heterocycloalkyl having from 1 to 2 heteroatoms as ring vertices selected from N, O and S; and

e) C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ haloalkyl, -C(O)NR^{1a}R^{1b}, and -CO₂R^{1a}; wherein R^{1a} and R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋₈ alkyl, C₆₋₁₀ aryl, and -C₁₋₆ alkylene-C₆₋₁₀ aryl;

wherein the group -X¹-R¹ is optionally substituted with 1 to 5 R^x substituents;

5 R^{2a} and R^{2e} are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -O-C₁₋₆ haloalkyl, -S-C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆ alkyl, -C₁₋₆ alkyl-S-C₁₋₆ alkyl, CN, and halogen, and at least one of R^{2a} and R^{2e} is other than hydrogen;

10 R^{2b}, R^{2c}, and R^{2d} are each independently selected from the group consisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -O-C₁₋₆ haloalkyl, -S-C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆ alkyl, -C₁₋₆ alkyl-S-C₁₋₆ alkyl, cyano, and halogen;

each R³ is independently selected from the group consisting of hydroxyl, C₁₋₄ alkyl, C₁₋₄ haloalkyl and C₁₋₄ hydroxyalkyl, and optionally two R³ groups on the same carbon atom are combined to form oxo (=O), and optionally two R³ groups and the carbon atoms they are attached to form a 3-6 membered ring with 0-2 heteroatoms as ring members selected from O, N, and S;

15 R⁴ is independently selected from the group consisting of -X²-OR^{4a}, -X²-NR^{4a}R^{4b}, -X²-CONR^{4a}R^{4b}, -X²-NR^{4a}-C(O)R^{4a}, -X²-NR^{4a}-C(O)NR^{4a}R^{4b}, -X²-NR^{4a}-C(O)OR^{4a}, -X²-NR^{4a}-C(O)-C₁₋₃ alkylene-OR^{4a} and -X²-NR^{4a}-C(O)-C₁₋₃ alkylene-NR^{4a}R^{4b};

20 wherein each X² is independently a bond, C(O), C₁₋₄ alkylene, C(O)-C₁₋₄ alkylene, and C₁₋₄ alkylene-C(O), and each R^{4a} and R^{4b} is independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, and C₁₋₄ haloalkyl;

each R⁵ is independently selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ haloalkyl, C₁₋₈ haloalkoxy, C₁₋₈ hydroxyalkyl, halogen, OH, CN, C(O)R^{5a} and CO₂R^{5a};


25 wherein each R^{5a} is independently selected from the group consisting of hydrogen, C₁₋₄ alkyl, and C₁₋₄ haloalkyl;

each R^x is independently selected from the group consisting of halogen, CN, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, C₁₋₄ hydroxy, C₂₋₄ alkenyl, C₃₋₆ cycloalkyl, CO₂-C₁₋₄ alkyl, and CONH₂;


30 the subscript m is 0, 1, 2, 3 or 4; and

the subscript n is 0, 1, 2 or 3.


[0042] In one group of embodiments for the compounds of formula (I), R^4 is selected from the group consisting of



[0043] In another group of embodiments for the compounds of formula (I), or a pharmaceutically acceptable salt thereof, R^4 is selected from the group consisting of



[0044] In yet another group of embodiments for the compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of



10 [0045] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the groups of embodiments noted above, in certain selected embodiments, X^1 is a bond; in other selected embodiments, X^1 is C(O) ; in still other selected embodiments, X^1 is C_{1-8} alkylene; in yet other selected embodiments, X^1 is C(O)-C_{1-4} alkylene or S(O)_2 .

15 [0046] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the groups or selected embodiments noted above, in some further embodiments, wherein R^1 is a 5- to 10-membered heteroaryl having from 1 to 4 heteroatoms as ring vertices selected from N, O and S; and wherein the group $\text{---X}^1\text{---R}^1$ is optionally substituted

with 1 to 4 R^x substituents. In still further embodiments, R¹ is selected from the group consisting of pyrazolyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, thiadiazolyl and pyrazinyl; and wherein the group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents.

5 [0047] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the groups or selected embodiments noted above, in some further embodiments, wherein R¹ is C₆₋₁₀ aryl; and wherein the group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents. In still further embodiments, R¹ is phenyl; and wherein the group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents.

10 [0048] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the groups or selected embodiments noted above, in some further embodiments, R¹ is C₃₋₈ cycloalkyl; and wherein the group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents. In still further embodiments, R¹ is selected from the group consisting of cyclobutyl, cyclopentyl and cyclohexyl; and wherein the group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents.

15 [0049] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the groups or selected embodiments noted above, in some further embodiments, R¹ is a 4- to 8-membered heterocycloalkyl having from 1 to 2 heteroatoms as ring vertices selected from N, O and S; and wherein the group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents. In still further selected embodiments, R¹ is selected from the group
20 consisting of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl; and wherein the group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents.

[0050] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the groups or selected embodiments noted above, in some further embodiments, R¹ is selected from the group consisting of C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ haloalkyl, -
25 C(O)NR^{1a}R^{1b}, and -CO₂R^{1a}, wherein R^{1a} and R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋₈ alkyl, C₆₋₁₀ aryl, and -C₁₋₆ alkylene-C₆₋₁₀ aryl; and wherein the group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents.

[0051] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the groups or selected embodiments noted above, in some further

embodiments, R^1 is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, and pyrazinyl; and wherein the group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x substituents.


[0052] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the embodiments noted above, in some further embodiments, ring
5 vertices a and b are CH; R^{2b} is H; ring vertex e is C(R^{2e}), and R^{2a} and R^{2e} are independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, -O- C_{1-6} haloalkyl, -S- C_{1-6} alkyl, - C_{1-6} alkyl-O- C_{1-6} alkyl, - C_{1-6} alkyl-S- C_{1-6} alkyl, CN, and halogen.

[0053] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the embodiments noted above, in some further embodiments, ring
10 vertices a and b are CH; R^{2b} is H; ring vertex e is C(R^{2e}), and R^{2a} and R^{2e} are independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy and halogen.

[0054] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the embodiments noted above, in some further embodiments, the
15 subscript n is 0, 1 or 2 and each R^5 , when present, is selected from the group consisting of F, Cl, CN, C_{1-4} alkyl and C_{1-4} alkoxy. In still further selected embodiments, the subscript n is 0, 1 or 2 and each R^5 , when present, is selected from the group consisting of F, Cl, CN, CH_3 and OCH_3 .


[0055] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the embodiments noted above, in some further embodiments, the
subscript m is 0, 1 or 2 and each R^3 , when present, is C_{1-4} alkyl.

20 [0056] In a particular group of embodiments of the compounds of formula (I), or a pharmaceutically acceptable salt thereof, R^1 is selected from the group consisting of phenyl or pyridyl, wherein the group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x substituents; ring
vertices a and b are CH; R^{2b} is H; ring vertex e is C(R^{2e}), and R^{2a} and R^{2e} are independently
25 selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy and halogen; m is 0, 1 or 2 and each R^3 , when present, is CH_3 ; R^4 is selected from the group consisting of




n is 0, 1 or 2 and each R⁵, when present, is selected from the group consisting of F, Cl, CN, CH₃ and OCH₃.


[0057] In some embodiments of the compounds of formula (I), or a pharmaceutically acceptable salt thereof, R¹ is selected from the group consisting of




[0058] In some embodiments of the compounds of formula (I), or a pharmaceutically acceptable salt thereof, $-X^1-R^1$ is selected from the group consisting of:




[0059] In some embodiments of the compounds of formula (I), or a pharmaceutically acceptable salt thereof, R¹ is selected from the group consisting of:




[0060] In some embodiments of the compounds of formula (I), or a pharmaceutically acceptable salt thereof, R^1 is selected from the group consisting of:




[0061] In some embodiments of the compounds of formula (I), or a pharmaceutically acceptable salt thereof, R^1 is selected from the group consisting of:



[0062] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the embodiments noted above, in some further embodiments, the group




is selected from the group consisting of



- 5 [0063] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the embodiments noted above, in some further embodiments, wherein n is 0.

- [0064] With reference to the compounds of formula (I), or a pharmaceutically acceptable salt thereof, as well as any of the embodiments noted above, in some further embodiments, the
 10 subscript n is 2 and the two R³ groups are on the same carbon atom and are combined to form oxo (=O).

[0065] In some selected embodiments, provided herein is a compound selected from the group consisting of:



or a pharmaceutically acceptable salt thereof.

[0066] In some embodiments, the compound of Formula (I) is a compound described in the Examples section and the accompanying Tables.

Preparation of Compounds

[0067] Certain compounds of the invention can be prepared following methodology as described in the Examples section of this document. In addition, the syntheses of certain
5 intermediate compounds that are useful in the preparation of compounds of the invention are also described.

B. Pharmaceutical Compositions

[0068] In addition to the compounds provided above, compositions for modulating C5a activity in humans and animals will typically contain a pharmaceutical carrier or diluent.

10 [0069] The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

15 [0070] The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy and drug delivery. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly
20 and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.

25 [0071] The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions and self emulsifications as described in U.S. Patent Application 2002-0012680, hard or soft capsules, syrups, elixirs, solutions, buccal patch, oral

gel, chewing gum, chewable tablets, effervescent powder and effervescent tablets. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, antioxidants and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as cellulose, silicon dioxide, aluminum oxide, calcium carbonate, sodium carbonate, glucose, mannitol, sorbitol, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example PVP, cellulose, PEG, starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated, enterically or otherwise, by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

[0072] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil. Additionally, emulsions can be prepared with a non-water miscible ingredient such as oils and stabilized with surfactants such as mono-diglycerides, PEG esters and the like.

[0073] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxy-ethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol,

or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more
5 flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0074] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard
10 paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

[0075] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting
15 agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[0076] The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a
20 mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The
25 emulsions may also contain sweetening and flavoring agents.

[0077] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. Oral solutions can be prepared in combination with, for example, cyclodextrin, PEG and surfactants.

[0078] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension
5 in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid
10 find use in the preparation of injectables.

[0079] The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
15 Such materials include cocoa butter and polyethylene glycols. Additionally, the compounds can be administered via ocular delivery by means of solutions or ointments. Still further, transdermal delivery of the subject compounds can be accomplished by means of iontophoretic patches and the like. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed. As used herein, topical application is also
20 meant to include the use of mouth washes and gargles.

[0080] The compounds of this invention may also be coupled a carrier that is a suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the
25 compounds of the invention may be coupled to a carrier that is a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices
30 may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like. In one

embodiment of the invention, the compound of the invention is coupled to a polymer or semipermeable polymer matrix that is formed as a stent or stent-graft device.

[0081] The pharmaceutical compositions of the present disclosure may be formulated with one or more additional therapeutic agents. The one or more additional therapeutic agent is selected
5 from the group consisting of corticosteroids, steroids, immunosuppressants, Immunoglobulin G agonists, Dipeptidyl peptidase IV inhibitors, Lymphocyte function antigen-3 receptor antagonists, Interleukin-2 ligands, Interleukin-1 beta ligand inhibitors, IL-2 receptor alpha subunit inhibitors, HGF gene stimulators, IL-6 antagonists, IL-5 antagonists, Alpha 1 antitrypsin stimulators, Cannabinoid receptor antagonists, Histone deacetylase inhibitors, AKT protein
10 kinase inhibitors, CD20 inhibitors, Abl tyrosine kinase inhibitors, JAK tyrosine kinase inhibitors, TNF alpha ligand inhibitors, Hemoglobin modulators, TNF antagonists, proteasome inhibitors, CD3 modulators, Hsp 70 family inhibitors, Immunoglobulin agonists, CD30 antagonists, tubulin antagonists, Sphingosine-1-phosphate receptor-1 agonists, connective tissue growth factor ligand inhibitors, caspase inhibitors, adrenocorticotrophic hormone ligands, Btk tyrosine kinase
15 inhibitors, Complement C1s subcomponent inhibitors, Erythropoietin receptor agonists, B-lymphocyte stimulator ligand inhibitors, Cyclin-dependent kinase-2 inhibitors, P-selectin glycoprotein ligand-1 stimulators, mTOR inhibitors, Elongation factor 2 inhibitors, Cell adhesion molecule inhibitors, Factor XIII agonists, Calcineurin inhibitors, Immunoglobulin G1 agonists, Inosine monophosphate dehydrogenase inhibitors, Complement C1s subcomponent inhibitors,
20 Thymidine kinase modulators, Cytotoxic T-lymphocyte protein-4 modulators, Angiotensin II receptor antagonists, Angiotensin II receptor modulators, TNF superfamily receptor 12A antagonists, CD52 antagonists, Adenosine deaminase inhibitors, T-cell differentiation antigen CD6 inhibitors, FGF-7 ligands, dihydroorotate dehydrogenase inhibitors, Syk tyrosine kinase inhibitors, Interferon type I receptor antagonists, Interferon alpha ligand inhibitors, Macrophage
25 migration inhibitory factor inhibitors, Integrin alpha-V/beta-6 antagonists, Cysteine protease stimulators, p38 MAP kinase inhibitors, TP53 gene inhibitors, Shiga like toxin I inhibitors, Fucosyltransferase 6 stimulators, Interleukin 22 ligands, IRS1 gene inhibitors, Protein kinase C stimulators, Protein kinase C alpha inhibitors, CD74 antagonists, Immunoglobulin gamma Fc receptor IIB antagonists, T-cell antigen CD7 inhibitors, CD95 antagonists, N acetylmannosamine
30 kinase stimulators, Cardiotrophin-1 ligands, Leukocyte elastase inhibitors, CD40 ligand receptor antagonists, CD40 ligand modulators, IL-17 antagonists, TLR-2 antagonists, Mannan-binding

lectin serine protease-2 (MASP-2) inhibitors, Factor B inhibitors, Factor D inhibitors, C3aR modulators, C5aR2 modulators, T cell receptor antagonists, PD-1 inhibitors, PD-L1 inhibitors, TIGIT inhibitors, TIM-3 inhibitors, LAG-3 inhibitors, VISTA inhibitors, STING agonists, IDO inhibitors, adenosine receptor modulators, CD39 inhibitors, CD73 inhibitors, antagonists of the chemokine receptors, especially CXCR1, CXCR2, CXCR3, CXCR4, CXCR7, CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, CCR7, CCR9, CX3CR1 and CXCR6, and combinations thereof.

[0082] In some embodiments, the one or more additional therapeutic agent is selected from the group consisting of obinutuzumab, rituximab, ocrelizumab, cyclophosphamide, prednisone, hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, halcinonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-valerate, halometasone, alclometasone dipropionate, beclomethasone, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate, fluprednidene acetate, hydrocortisone-17-butyrate, hydrocortisone-17-aceponate, hydrocortisone-17-buteprate, ciclesonide and prednicarbate, GB-0998, immuglo, begelomab, alefacept, aldesleukin, gevokizumab, daclizumab, basiliximab, inolimomab, beperminogene perplasmid, sirukumab, tocilizumab, clazakizumab, mepolizumab, fingolimod, panobinostat, triciribine, nilotinib, imatinib, tofacitinib, momelotinib, peficitinib, itacitinib, infliximab, PEG-bHb-CO, etanercept, ixazomib, bortezomib, muromonab, otelixizumab, gusperimus, brentuximab vedotin, Ponesimod, KRP-203, FG-3019, emricasan, corticotropin, ibrutinib, cinryze, conestat, methoxy polyethylene glycol-epoetin beta, belimumab, blisibimod, atacicept, seliciclib, neihulizumab, everolimus, sirolimus, denileukin diftitox, LMB-2, natalizumab, catridecacog, ciclosporin, tacrolimus, voclosporin, voclosporin, canakinumab, mycophenolate, mizoribine, CE-1145, TK-DLI, abatacept, belatacept, olmesartan medoxomil, sparsentan, TXA-127, BIIB-023, alemtuzumab, pentostatin, itolizumab, palifermin, leflunomide, PRO-140, cenicriviroc, fostamatinib, anifrolumab, sifalimumab, BAX-069, BG-00011, losmapimod, QPI-1002, ShigamAbs, TZ-101, F-652, reparixin, ladarixin, PTX-9908, aganirsen, APH-703, sotrastaurin, sotrastaurin, milatuzumab, SM-101, T-Guard, APG-101, DEX-M74, cardiotrophin-1, tiprelestat, ASKP-1240, BMS-986004, HPH-116, KD-025, OPN-305, TOL-101, defibrotide,

pomalidomide, Thymoglobulin, laquinimod, remestemcel-L, Equine antithymocyte immunoglobulin, Stempeucel, LIV-Gamma, Octagam 10%, t2c-001, 99mTc-sestamibi, Clairyg, Prosorba, pomalidomide, laquinimod, teplizumab, FCRx, solnatide, foralumab, ATIR-101, BPX-501, ACP-01, ALLO-ASC-DFU, irbesartan + propagermanium, ApoCell, cannabidiol, RGI-5 2001, saratin, anti-CD3 bivalent antibody-diphtheria toxin conjugate, NOX-100, LT-1951, OMS721, ALN-CC5, ACH-4471, AMY-101, Acthar gel, and CD4+CD25+ regulatory T-cells, MEDI7814, P32, P59, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, CCX354, CCX721, CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX587, CCX624, CCX282, CCX025, CCX507, CCX430, CCX765, CCX758, CCX771, CCX662, CCX650, and 10 combinations thereof. Further discussions of combination therapy are included in the “Methods of Use” section of this application.

A. Methods of Use

[0083] The compounds of the invention may be used as agonists, (preferably) antagonists, partial agonists, inverse agonists, of C5a receptors in a variety of contexts, both *in vitro* and *in vivo*. In one embodiment, the compounds of the invention are C5aR antagonist that can be used 15 to inhibit the binding of C5a receptor ligand (*e.g.*, C5a) to C5a receptor *in vitro* or *in vivo*. In general, such methods comprise the step of contacting a C5a receptor with a sufficient amount of one or more C5a receptor modulators as provided herein, in the presence of C5a receptor ligand in aqueous solution and under conditions otherwise suitable for binding of the ligand to C5a 20 receptor. The C5a receptor may be present in suspension (*e.g.*, in an isolated membrane or cell preparation), in a cultured or isolated cell, or in a tissue or organ.

[0084] Preferably, the amount of C5a receptor modulator contacted with the receptor should be sufficient to inhibit C5a binding to C5a receptor *in vitro* as measured, for example, using a radioligand binding assay, calcium mobilization assay, or chemotaxis assay as described herein.

25 [0085] In one embodiment of the invention, the C5a modulators of the invention are used to modulate, preferably inhibit, the signal-transducing activity of a C5a receptor, for example, by contacting one or more compound(s) of the invention with a C5a receptor (either *in vitro* or *in vivo*) under conditions suitable for binding of the modulator(s) to the receptor. The receptor may be present in solution or suspension, in a cultured or isolated cell preparation or within a patient.

Any modulation of the signal transducing activity may be assessed by detecting an effect on calcium ion calcium mobilization or by detecting an effect on C5a receptor-mediated cellular chemotaxis. In general, an effective amount of C5a modulator(s) is an amount sufficient to modulate C5a receptor signal transducing activity *in vitro* within a calcium mobilization assay or
5 C5a receptor-mediated cellular chemotaxis within a migration assay.

[0086] When compounds of the invention are used to inhibit C5a receptor-mediated cellular chemotaxis, preferably leukocyte (*e.g.*, neutrophil) chemotaxis, in an *in vitro* chemotaxis assay, such methods comprise contacting white blood cells (particularly primate white blood cells, especially human white blood cells) with one or more compounds of the invention. Preferably
10 the concentration is sufficient to inhibit chemotaxis of white blood cells in an *in vitro* chemotaxis assay, so that the levels of chemotaxis observed in a control assay are significantly higher, as described above, than the levels observed in an assay to which a compound of the invention has been added.

[0087] In another embodiment, the compounds of the present invention further can be used for
15 treating patients suffering from conditions that are responsive to C5a receptor modulation. As used herein, the term "treating" or "treatment" encompasses both disease-modifying treatment and symptomatic treatment, either of which may be prophylactic (*i.e.*, before the onset of symptoms, in order to prevent, delay or reduce the severity of symptoms) or therapeutic (*i.e.*, after the onset of symptoms, in order to reduce the severity and/or duration of symptoms). As
20 used herein, a condition is considered "responsive to C5a receptor modulation" if modulation of C5a receptor activity results in the reduction of inappropriate activity of a C5a receptor. As used herein, the term "patients" include primates (especially humans), domesticated companion animals (such as dogs, cats, horses, and the like) and livestock (such as cattle, pigs, sheep, and the like), with dosages as described herein.

25 *Conditions that can be treated by C5a modulation:*

[0088] Autoimmune disorders-- *e.g.*, Rheumatoid arthritis, systemic lupus erythematosus, Guillain-Barre syndrome, pancreatitis, lupus nephritis, lupus glomerulonephritis, psoriasis, Crohn's disease, vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, dense deposit disease, pemphigus, pemphigoid, scleroderma, myasthenia

gravis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome (and associated glomerulonephritis and pulmonary hemorrhage), C3-glomerulopathy, C3-glomerulonephritis, membranoproliferative glomerulonephritis, Kawasaki disease, IGs nephropathy, immunovascularitis, tissue graft rejection, graft versus host disease, hyperacute rejection of transplanted organs; and the like.

[0089] Inflammatory disorders and related conditions-- *e.g.*, Neutropenia, sepsis, septic shock, Alzheimer's disease, multiple sclerosis, neutrophilia, stroke, inflammatory bowel disease (IBD), inflammation associated with severe burns, lung injury, and ischemia-reperfusion injury, osteoarthritis, as well as acute (adult) respiratory distress syndrome (ARDS), chronic pulmonary obstructive disorder (COPD), systemic inflammatory response syndrome (SIRS), atopic dermatitis, psoriasis, chronic urticaria and multiple organ dysfunction syndrome (MODS) Hemolytic uremic syndrome, atypical hemolytic uremic syndrome (aHUS). Also included are pathologic sequellae associated with insulin-dependent diabetes mellitus (including diabetic retinopathy), lupus nephropathy, Heyman nephritis, membranous nephritis and other forms of glomerulonephritis, contact sensitivity responses, and inflammation resulting from contact of blood with artificial surfaces that can cause complement activation, as occurs, for example, during extracorporeal circulation of blood (*e.g.*, during hemodialysis or via a heart-lung machine, for example, in association with vascular surgery such as coronary artery bypass grafting or heart valve replacement), or in association with contact with other artificial vessel or container surfaces (*e.g.*, ventricular assist devices, artificial heart machines, transfusion tubing, blood storage bags, plasmapheresis, plateletpheresis, and the like). Also included are diseases related to ischemia/reperfusion injury, such as those resulting from transplants, including solid organ transplant, and syndromes such as ischemic reperfusion injury, ischemic colitis and cardiac ischemia. Compounds of the instant invention may also be useful in the treatment of age-related macular degeneration (Hageman et al, *P.N.A.S.* **102**: 7227-7232, 2005).

[0090] Cardiovascular and Cerebrovascular Disorders--*e.g.*, myocardial infarction, coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion, atherosclerosis, traumatic central nervous system injury, and ischemic heart disease. In one embodiment, an effective amount of a compound of the invention may be administered to a patient at risk for myocardial infarction or thrombosis (*i.e.*, a patient who has one or more recognized risk factor for

myocardial infarction or thrombosis, such as, but not limited to, obesity, smoking, high blood pressure, hypercholesterolemia, previous or genetic history of myocardial infarction or thrombosis) in order reduce the risk of myocardial infarction or thrombosis.

[0091] Oncologic Diseases or Disorders--*e.g.*, melanoma, lung cancer, lymphoma, sarcoma, carcinoma, fibrosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, lymphangiosarcoma, synovioma, mesothelioma, meningioma, leukemia, lymphoma, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, papillary carcinoma, cystadenocarcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, wilm's tumor, pleomorphic adenoma, liver cell papilloma, renal tubular adenoma, cystadenoma, papilloma, adenoma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma, chondroma, lipoma and fibroma.

[0092] Diseases of Vasculitis – Vasculitic diseases are characterized by inflammation of the vessels. Infiltration of leukocytes leads to destruction of the vessel walls, and the complement pathway is believed to play a major role in initiating leukocyte migration as well as the resultant damage manifested at the site of inflammation (Vasculitis, Second Edition, Edited by Ball and Bridges, Oxford University Press, pp 47-53, 2008). The compounds provided in the present invention can be used to treat leukoclastic vasculitis, Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, immune vasculitis Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, Henoch-Schonlein purpura, polyarteritis nodosa, Rapidly Progressive Glomerulonephritis (RPGN), cryoglobulinaemia, giant cell arteritis (GCA), Behcet's disease and Takayasu's arteritis (TAK).

[0093] HIV infection and AIDS -- C5a receptor modulators provided herein may be used to inhibit HIV infection, delay AIDS progression or decrease the severity of symptoms or HIV infection and AIDS.

[0094] Neurodegenerative disorders and related diseases-- Within further aspects, C5a antagonists provided herein may be used to treat Alzheimer's disease, multiple sclerosis, and cognitive function decline associated with cardiopulmonary bypass surgery and related procedures.

[0095] In one embodiment of the invention, the compounds of the invention can be used for the treatment of diseases selected from the group consisting of sepsis (and associated disorders), COPD, rheumatoid arthritis, lupus nephritis and multiple sclerosis.

5 [0096] Treatment methods provided herein include, in general, administration to a patient an effective amount of one or more compounds provided herein. Suitable patients include those patients suffering from or susceptible to (*i.e.*, prophylactic treatment) a disorder or disease identified herein. Typical patients for treatment as described herein include mammals, particularly primates, especially humans. Other suitable patients include domesticated companion animals such as a dog, cat, horse, and the like, or a livestock animal such as cattle,
10 pig, sheep and the like.

[0097] In general, treatment methods provided herein comprise administering to a patient an effective amount of a compound one or more compounds provided herein. In a preferred embodiment, the compound(s) of the invention are preferably administered to a patient (*e.g.*, a human) orally or topically. The effective amount may be an amount sufficient to modulate C5a
15 receptor activity and/or an amount sufficient to reduce or alleviate the symptoms presented by the patient. Preferably, the amount administered is sufficient to yield a plasma concentration of the compound (or its active metabolite, if the compound is a pro-drug) high enough to detectably inhibit white blood cell (*e.g.*, neutrophil) chemotaxis *in vitro*. Treatment regimens may vary depending on the compound used and the particular condition to be treated; for treatment of most
20 disorders, a frequency of administration of 4 times daily or less is preferred. In general, a dosage regimen of 2 times daily is more preferred, with once a day dosing particularly preferred. It will be understood, however, that the specific dose level and treatment regimen for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of
25 administration, rate of excretion, drug combination (*i.e.*, other drugs being administered to the patient) and the severity of the particular disease undergoing therapy, as well as the judgment of the prescribing medical practitioner. In general, the use of the minimum dose sufficient to provide effective therapy is preferred. Patients may generally be monitored for therapeutic effectiveness using medical or veterinary criteria suitable for the condition being treated or
30 prevented.

[0098] Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment or preventions of conditions involving pathogenic C5a activity (about 0.5 mg to about 7 g per human patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary
5 depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient. For compounds administered orally, transdermally, intravenously, or subcutaneously, it is preferred that sufficient amount of the compound be administered to achieve a serum concentration of 5 ng (nanograms)/mL-10 µg (micrograms)/mL serum, more preferably sufficient compound to
10 achieve a serum concentration of 20 ng-1 µg/ml serum should be administered, most preferably sufficient compound to achieve a serum concentration of 50 ng/ml-200 ng/ml serum should be administered. For direct injection into the synovium (for the treatment of arthritis) sufficient compounds should be administered to achieve a local concentration of approximately 1 micromolar.

15 [0099] Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most disorders, a dosage regimen of 4 times daily, three times daily, or less is preferred, with a dosage regimen of once daily or 2 times daily being particularly preferred. It will be understood, however, that the specific dose level for any
20 particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination (*i.e.*, other drugs being administered to the patient), the severity of the particular disease undergoing therapy, and other factors, including the judgment of the prescribing medical practitioner.

Combination Therapy

25 [0100] The presently disclosed compounds may be used in combination with one or more additional therapeutic agents that are used in the treatment, prevention, suppression or amelioration of the diseases or conditions for which compounds and compositions of the present invention are useful. Such one or more additional therapeutic agents may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a

compound or composition of the present invention. When a compound or composition of the present invention is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound or composition of the present invention is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients or therapeutic agents, in addition to a compound or composition of the present invention.

[0101] Examples of the the one or more additional therapeutic agents are corticosteroids, steroids, immunosuppressants, Immunoglobulin G agonists, Dipeptidyl peptidase IV inhibitors, Lymphocyte function antigen-3 receptor antagonists, Interleukin-2 ligands, Interleukin-1 beta ligand inhibitors, IL-2 receptor alpha subunit inhibitors, HGF gene stimulators, IL-6 antagonists, IL-5 antagonists, Alpha 1 antitrypsin stimulators, Cannabinoid receptor antagonists, Histone deacetylase inhibitors, AKT protein kinase inhibitors, CD20 inhibitors, Abl tyrosine kinase inhibitors, JAK tyrosine kinase inhibitors, TNF alpha ligand inhibitors, Hemoglobin modulators, TNF antagonists, proteasome inhibitors, CD3 modulators, Hsp 70 family inhibitors, Immunoglobulin agonists, CD30 antagonists, tubulin antagonists, Sphingosine-1-phosphate receptor-1 agonists, connective tissue growth factor ligand inhibitors, caspase inhibitors, adrenocorticotrophic hormone ligands, Btk tyrosine kinase inhibitors, Complement C1s subcomponent inhibitors, Erythropoietin receptor agonists, B-lymphocyte stimulator ligand inhibitors, Cyclin-dependent kinase-2 inhibitors, P-selectin glycoprotein ligand-1 stimulators, mTOR inhibitors, Elongation factor 2 inhibitors, Cell adhesion molecule inhibitors, Factor XIII agonists, Calcineurin inhibitors, Immunoglobulin G1 agonists, Inosine monophosphate dehydrogenase inhibitors, Complement C1s subcomponent inhibitors, Thymidine kinase modulators, Cytotoxic T-lymphocyte protein-4 modulators, Angiotensin II receptor antagonists, Angiotensin II receptor modulators, TNF superfamily receptor 12A antagonists, CD52 antagonists, Adenosine deaminase inhibitors, T-cell differentiation antigen CD6 inhibitors, FGF-7 ligands, dihydroorotate dehydrogenase inhibitors, Syk tyrosine kinase inhibitors, Interferon type I receptor antagonists, Interferon alpha ligand inhibitors, Macrophage migration inhibitory factor inhibitors, Integrin alpha-V/beta-6 antagonists, Cysteine protease stimulators, p38 MAP kinase inhibitors, TP53 gene inhibitors, Shiga like toxin I inhibitors, Fucosyltransferase 6 stimulators, Interleukin 22 ligands, IRS1 gene inhibitors, Protein kinase C stimulators, Protein kinase C alpha inhibitors, CD74 antagonists, Immunoglobulin gamma Fc receptor IIB

antagonists, T-cell antigen CD7 inhibitors, CD95 antagonists, N acetylmannosamine kinase stimulators, Cardiotrophin-1 ligands, Leukocyte elastase inhibitors, CD40 ligand receptor antagonists, CD40 ligand modulators, IL-17 antagonists, TLR-2 antagonists, Mannan-binding lectin serine protease-2 (MASP-2) inhibitors, Factor B inhibitors, Factor D inhibitors, C3aR modulators, C5aR2 modulators, T cell receptor antagonists, PD-1 inhibitors, PD-L1 inhibitors, TIGIT inhibitors, TIM-3 inhibitors, LAG-3 inhibitors, VISTA inhibitors, STING agonists, IDO inhibitors, adenosine receptor modulators, CD39 inhibitors, CD73 inhibitors, antagonists of the chemokine receptors, especially CXCR1, CXCR2, CXCR3, CXCR4, CXCR7, CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, CCR7, CCR9, CX3CR1 and CXCR6, and combinations thereof.

10 [0102] In some embodiments, the additional therapeutic agent used in the therapeutic methods herein, is selected from the group consisting of obinutuzumab, rituximab, ocrelizumab, cyclophosphamide, prednisone, hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, triamcinolone acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, 15 halcinonide, betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone, hydrocortisone-17-valerate, halometasone, alclometasone dipropionate, beclomethasone, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate, fluprednidene acetate, hydrocortisone-17-butyrate, hydrocortisone-17- 20 aceponate, hydrocortisone-17-buteprate, ciclesonide and prednicarbate, GB-0998, immuglo, begelomab, alefacept, aldesleukin, gevokizumab, daclizumab, basiliximab, inolimomab, beperminogene perplasmid, sirukumab, tocilizumab, clazakizumab, mepolizumab, fingolimod, panobinostat, triciribine, nilotinib, imatinib, tofacitinib, momelotinib, peficitinib, itacitinib, infliximab, PEG-bHb-CO, etanercept, ixazomib, bortezomib, muromonab, otelixizumab, 25 gusperimus, brentuximab vedotin, Ponesimod, KRP-203, FG-3019, emricasan, corticotropin, ibrutinib, cinryze, conestat, methoxy polyethylene glycol-epoetin beta, belimumab, blisibimod, atacicept, seliciclib, neihulizumab, everolimus, sirolimus, denileukin diftitox, LMB-2, natalizumab, catridecacog, ciclosporin, tacrolimus, voclosporin, voclosporin, canakinumab, mycophenolate, mizoribine, CE-1145, TK-DLI, abatacept, belatacept, olmesartan medoxomil, 30 sparsentan, TXA-127, BIIB-023, alemtuzumab, pentostatin, itolizumab, palifermin, leflunomide, PRO-140, cenicriviroc, fostamatinib, anifrolumab, sifalimumab, BAX-069, BG-00011,

losmapimod, QPI-1002, ShigamAbs, TZ-101, F-652, reparixin, ladarixin, PTX-9908, aganirsen, APH-703, sotrastaurin, sotrastaurin, milatuzumab, SM-101, T-Guard, APG-101, DEX-M74, cardiotrophin-1, tiprelestat, ASKP-1240, BMS-986004, HPH-116, KD-025, OPN-305, TOL-101, defibrotide, pomalidomide, Thymoglobulin, laquinimod, remestemcel-L, Equine antithymocyte immunoglobulin, Stempeucel, LIV-Gamma, Octagam 10%, t2c-001, 99mTc-sestamibi, Clairyg, Prosorba, pomalidomide, laquinimod, teplizumab, FCRx, solnatide, foralumab, ATIR-101, BPX-501, ACP-01, ALLO-ASC-DFU, irbesartan + propagermanium, ApoCell, cannabidiol, RGI-2001, saratin, anti-CD3 bivalent antibody-diphtheria toxin conjugate, NOX-100, LT-1951, OMS721, ALN-CC5, ACH-4471, AMY-101, Acthar gel, and CD4+CD25+ regulatory T-cells, MEDI7814, P32, P59, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, CCX354, CCX721, CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX587, CCX624, CCX282, CCX025, CCX507, CCX430, CCX765, CCX758, CCX771, CCX662, CCX650, and combinations thereof.

[0103] The disease or disorder being treated will determine which additional therapeutic agent or therapeutic agents are most appropriately administered in combination with the compounds of the present invention – such determination can be made by a person of skill in the art.

[0104] The weight ratio of the compound of the present invention to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a compound of the present invention is combined with an NSAID the weight ratio of the compound of the present invention to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of the present invention and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

25 *Non-Pharmaceutical Applications*

[0105] In another aspect of the invention, the compounds of the invention can be used in a variety of non-pharmaceutical *in vitro* and *in vivo* application. For example, the compounds of the invention may be labeled and used as probes for the detection and localization of C5a receptor (cell preparations or tissue sections samples). The compounds of the invention may also

be used as positive controls in assays for C5a receptor activity, *i.e.*, as standards for determining the ability of a candidate agent to bind to C5a receptor, or as radiotracers for positron emission tomography (PET) imaging or for single photon emission computerized tomography (SPECT). Such methods can be used to characterize C5a receptors in living subjects. For example, a C5a
5 receptor modulator may be labeled using any of a variety of well known techniques (*e.g.*, radiolabeled with a radionuclide such as tritium), and incubated with a sample for a suitable incubation time (*e.g.*, determined by first assaying a time course of binding). Following incubation, unbound compound is removed (*e.g.*, by washing), and bound compound detected using any method suitable for the label employed (*e.g.*, autoradiography or scintillation counting
10 for radiolabeled compounds; spectroscopic methods may be used to detect luminescent groups and fluorescent groups). As a control, a matched sample containing labeled compound and a greater (*e.g.*, 10-fold greater) amount of unlabeled compound may be processed in the same manner. A greater amount of detectable label remaining in the test sample than in the control indicates the presence of C5a receptor in the sample. Detection assays, including receptor
15 autoradiography (receptor mapping) of C5a receptor in cultured cells or tissue samples may be performed as described by Kuhar in sections 8.1.1 to 8.1.9 of Current Protocols in Pharmacology (1998) John Wiley & Sons, New York.

[0106] The compounds provided herein may also be used within a variety of well known cell separation methods. For example, modulators may be linked to the interior surface of a tissue
20 culture plate or other support, for use as affinity ligands for immobilizing and thereby isolating, C5a receptors (*e.g.*, isolating receptor-expressing cells) *in vitro*. In one preferred application, a modulator linked to a fluorescent marker, such as fluorescein, is contacted with the cells, which are then analyzed (or isolated) by fluorescence activated cell sorting (FACS).

I. Examples

25 [0107] The following examples are offered to illustrate, but not to limit the claimed invention.

[0108] Reagents and solvents used below can be obtained from commercial sources such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA). ¹H-NMR spectra were recorded on a Varian Mercury 400 MHz NMR spectrometer. Significant peaks are provided relative to

TMS and are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet) and number of protons. Mass spectrometry results are reported as the ratio of mass over charge, followed by the relative abundance of each ion (in parenthesis). In the examples, a single m/e value is reported for the M+H (or, as noted, M-H) ion containing the most common atomic isotopes. Isotope patterns correspond to the expected formula in all cases. Electrospray ionization (ESI) mass spectrometry analysis was conducted on a Hewlett-Packard MSD electrospray mass spectrometer using the HP1100 HPLC for sample delivery. Normally the analyte was dissolved in methanol at 0.1 mg/mL and 1 microliter was infused with the delivery solvent into the mass spectrometer, which scanned from 100 to 1500 daltons. All compounds could be analyzed in the positive ESI mode, using acetonitrile / water with 1% formic acid as the delivery solvent. The compounds provided below could also be analyzed in the negative ESI mode, using 2 mM NH₄OAc in acetonitrile / water as delivery system.

[0109] The following abbreviations are used in the Examples and throughout the description of the invention:

EtOH: Ethanol

EtONa: Sodium ethoxide

THF: Tetrahydrofuran

TLC: Thin layer chromatography

MeOH: Methanol

[0110] Compounds within the scope of this invention can be synthesized as described below, using a variety of reactions known to the skilled artisan. One skilled in the art will also recognize that alternative methods may be employed to synthesize the target compounds of this invention, and that the approaches described within the body of this document are not exhaustive, but do provide broadly applicable and practical routes to compounds of interest.


[0111] Certain molecules claimed in this patent can exist in different enantiomeric and diastereomeric forms and all such variants of these compounds are claimed.

[0112] The detailed description of the experimental procedures used to synthesize key compounds in this text lead to molecules that are described by the physical data identifying them as well as by the structural depictions associated with them.

[0113] Those skilled in the art will also recognize that during standard work up procedures in organic chemistry, acids and bases are frequently used. Salts of the parent compounds are sometimes produced, if they possess the necessary intrinsic acidity or basicity, during the experimental procedures described within this patent.

Example 1

10 **Synthesis of 1-(4-(5-(3,5-dichloropyridin-2-yl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-difluorophenyl)urea**



[0114] Step a: A mixture of 3-methyl-2-nitro-phenol (50.0 g, 326.5 mmol), 1-iodo-2-methyl-propane (184.0 g, 1.0 mol) and Cs_2CO_3 (326.0 g, 1.0 mol) in acetone (500 mL) was stirred overnight under reflux. It was then cooled to room temperature and filtered through Celite. The filtrate was collected and concentrated under reduced pressure. The obtained solid was dissolved into EtOAc, washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure to afford 1-isobutoxy-3-methyl-2-nitro-benzene. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.26 (t,

$J = 8.0$ Hz, 1H), 6.82 (m, 2H), 3.78 (d, $J = 6.8$ Hz, 2H), 2.94 (s, 3H), 2.07 (m, 1H), 0.98 (d, $J = 6.4$ Hz, 6H).

[0115] A pressure vessel containing 1-isobutoxy-3-methyl-2-nitro-benzene (130.4 g, 623.2 mmol), 10% Pd/C (25 g, 50% wet) and EtOH (750 mL) was agitated under a hydrogen atmosphere at 45 psi for 3 h. The mixture was filtered through Celite. The filtrate was collected and concentrated under reduced pressure to yield 2-isobutoxy-6-methyl-aniline. $C_{11}H_{18}NO$ [M + H]⁺ 180.2, found 180.2.

[0116] *Caution: Diazonium formation could be potentially dangerous, please handle with care and wear proper personal protection equipment!*

10 [0117] Step b: To 100 mL of concentrated HCl at -10 °C was added isobutoxy-6-methyl aniline (26.4 g, 147.3 mmol) portionwise to obtain a stirrable suspension. After stirring for 30 min at the same temperature, a solution of $NaNO_2$ (12.2 g, 176.8 mmol) in water (25 mL) was added dropwise over 20 min to obtain the diazonium salt.

15 [0118] To the above diazonium salt was added tin(II) chloride dihydrate (83.0 g, 367.8 mmol) in concentrated HCl (120 mL) portionwise. The obtained mixture was then stirred for 10 min at -10 °C followed by 1 h at room temperature. The mixture was then diluted into DCM (400 mL) and water. The organic layer was separated, dried over Na_2SO_4 and concentrated on a rotary evaporator under reduced pressure to yield (2-isobutoxy-6-methyl-phenyl)hydrazine hydrochloride. $C_{11}H_{19}N_2O$ [M + H]⁺ 195.1, found 195.1.

20 [0119] Step c: To a stirred suspension of (2-isobutoxy-6-methylphenyl)hydrazine hydrochloride (8.0 g, 39.9 mmol) in EtOH (60 mL) and glacial acetic acid (12 mL, 208 mmol) was added *tert*-butyl 3-cyano-4-oxopiperidine-1-carboxylate (5.0 g, 22.3 mmol) at room temperature. The resulting mixture was stirred under reflux for 16 h. After removal of solvent under reduced pressure, the residue was dissolved in EtOAc and washed with 2 N aqueous NaOH, brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 55% EtOAc in hexanes) to give *tert*-butyl 3-amino-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) m/z calculated for $C_{22}H_{33}N_4O_3$ [M + H]⁺ 401.2, found 401.2.

[0120] *Caution: Diazonium formation could be potentially dangerous, please handle with care and wear proper personal protection equipment!*

[0121] Isoamyl nitrite (96%, 4.0 mL, 28.6 mmol) was added slowly at room temperature to a mixture of *tert*-butyl 3-amino-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-
5 pyrazolo[4,3-*c*]pyridine-5-carboxylate (3.0 g, 8.1 mmol), CuBr (4.0 g, 27.9 mmol) and MeCN (50 mL) in a 250 mL round bottom flask under magnetic stirring. The resulting mixture was stirred at room temperature for 1 h, diluted with EtOAc, filtered through Celite, washed with saturated aqueous NH₄Cl solution, and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (2 to 25%
10 EtOAc in hexanes) to give *tert*-butyl 3-bromo-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₂H₃₁BrN₃O₃ [M + H]⁺ 464.1, found 464.2.

[0122] Step d: A mixture of 4-bromo-2,5-difluoroaniline (1.5 g, 7.2 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.2 g, 8.7 mmol), KOAc (1.8 g, 18.3 mmol) and
15 Pd(dppf)Cl₂ complex with dichloromethane (580.0 mg, 0.7 mmol) in dioxane (12 mL) was stirred at 95 °C for 2 h under nitrogen. The mixture was then cooled to room temperature and filtered over Celite. The filtrate was collected, concentrated under reduced pressure, and purified by silica gel flash chromatography (0 to 50% EtOAc in hexanes) to give 2,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline. MS: (ES) *m/z* calculated for C₁₂H₁₇BF₂NO₂ [M +
20 H]⁺ 256.1, found 256.2.

[0123] To a suspension of *tert*-butyl 3-bromo-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (125.0 mg, 0.3 mmol), 2,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (75.0 mg, 0.3 mmol), Na₂CO₃ (85.0 mg, 0.8 mmol) in dioxane (4 mL) and water (1 mL) was added Pd(dppf)Cl₂ complex with
25 dichloromethane (26.0 mg, 0.03 mmol). The reaction mixture was degassed (N₂) for 2 min and stirred under N₂ at 95 °C for 6 h. The reaction mixture was diluted with EtOAc, filtered through Celite, washed with brine, and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 40% EtOAc in hexanes) to give *tert*-butyl 3-(4-amino-2,5-difluorophenyl)-2-(2-isobutoxy-6-methylphenyl)-

2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₈H₃₅F₂N₄O₃ [M + H]⁺ 513.3, found 513.3.

[0124] Step e: To a stirred solution of *tert*-butyl 3-(4-amino-2,5-difluorophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (0.5 g, 2.0 mmol) in anhydrous THF (5 mL) was added *N,N*-disopropylethylamine (0.6 g, 4.8 mmol) and trimethylsilylisocyanate (0.3 g, 2.6 mmol). The reaction mixture was stirred at room temperature for 16 h. After completion, the reaction mixture was diluted with EtOAc, washed with brine, and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 40% EtOAc in hexanes) to afford *tert*-butyl-3-(2,5-difluoro-4-ureidophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated C₂₉H₃₆F₂N₅O₄ [M + H]⁺ 556.3, found 556.3.

[0125] Step f: To a solution of *tert*-butyl-3-(2,5-difluoro-4-ureidophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (1.2 g, 3.6 mmol), in dichloromethane (10 mL) was added 4 N HCl in dioxane (3.0 mL, 12.0 mmol). The resulting mixture was stirred at room temperature for 2 h. After completion of the reaction, the solvent was diluted with water and saturated aqueous NaHCO₃ and extracted with EtOAc, washed with brine and dried over MgSO₄. The solvent was removed under reduced pressure to give 1-(2,5-difluoro-4-(2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)phenyl)urea. MS: (ES) *m/z* calculated for C₂₄H₂₈F₂N₅O₂ [M + H]⁺ 456.2, found 456.2.

[0126] Step g: To a suspension of 1-(2,5-difluoro-4-(2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)phenyl)urea (3.0 g, 6.6 mmol) in DMSO (10 mL) was added 3,5-dichloro-5-fluoro pyridine (1.6 g, 9.9 mmol) and Li₂CO₃ (1.9 g, 25.7 mmol) at room temperature. The resulting mixture was stirred at 90 °C for 4 h. After completion of the reaction, the mixture was cooled to room temperature, and diluted with EtOAc. The organic layer was washed with brine, and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (10 to 60% EtOAc in hexanes) to afford 1-(4-(5-(3,5-dichloropyridin-2-yl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea. ¹H NMR (400 MHz,


CD₃OD): δ 8.15 (d, $J = 2.3$ Hz, 1H), 8.02 (dd, $J = 7.1, 12.5$ Hz, 1H), 7.84 (d, $J = 2.3$ Hz, 1H), 7.32 (t, $J = 7.8$ Hz, 1H), 6.92 (d, $J = 8.2$ Hz, 1H), 6.89 (d, $J = 7.5$ Hz, 1H), 6.82 (dd, $J = 6.3, 11.3$ Hz, 1H), 4.87 (br, 2H), 4.39 (s, 2H), 3.70 - 3.82 (m, 4H), 3.65 (dd, $J = 7.1, 9.0$ Hz, 1H), 3.07 (t, $J = 6.7$ Hz, 2H), 2.02 (s, 3H), 1.85–1.95 (m, 1H), 0.85 (d, $J = 7.0$ Hz, 6H). MS: (ES) m/z

5 calculated C₂₉H₂₉Cl₂F₂N₆O₂ [M + H]⁺ 601.2, found 601.5.

Example 2

Synthesis of 4-(5-(5-(*tert*-butyl)-2-methylphenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)benzamide

10




[0127] Step a: A mixture of *tert*-butyl 3-bromo-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (120.0 mg, 0.26 mmol), (4-cyanophenyl)boronic acid (100.0 mg, 0.68 mmol), Pd(PPh₃)₄ (45.0 mg, 0.04 mmol) and K₂CO₃ (125.0 mg, 0.9 mmol) in toluene (2 mL) and water (0.3 mL) was stirred at 110 °C for 3 h under N₂. The mixture was cooled to room temperature, quenched with water, and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 40% EtOAc in hexanes) to yield *tert*-butyl 3-(4-cyanophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₉H₃₅N₄O₃ [M + H]⁺ 487.3, found 487.2.

- [0128] Step b: A mixture of *tert*-butyl 3-(4-cyanophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (92.0 mg, 0.2 mmol) and 4 N HCl in dioxane (2.0 mL, 8.0 mmol) in dichloromethane (2 mL) was stirred at room temperature for 1 h. The mixture was basified with saturated aqueous NaHCO₃ and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatograph (0 to 25% MeOH in dichloromethane) to yield 4-(2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)benzotrile. MS: (ES) *m/z* calculated for C₂₄H₂₇N₄O [M + H]⁺ 387.2, found 387.2.
- [0129] Step c: A mixture of 4-(2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)benzotrile (56.0 mg, 0.15 mmol), 2-bromo-4-(*tert*-butyl)-1-methylbenzene (131.0 mg, 0.58 mmol), Pd(OAc)₂ (12.0 mg, 0.05 mmol), X-Phos (60.0 mg, 0.13 mmol) and Cs₂CO₃ (141.0 mg, 0.43 mmol) in dioxane (2 mL) was stirred at 110 °C for 1 h under N₂. The mixture was cooled to room temperature, diluted with water, and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 35% EtOAc in hexanes) to yield 4-(5-(5-(*tert*-butyl)-2-methylphenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)benzotrile. MS: (ES) *m/z* calculated for C₃₅H₄₁N₄O [M + H]⁺ 533.3, found 533.3.
- [0130] Step d: To a mixture of 4-(5-(5-(*tert*-butyl)-2-methylphenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)benzotrile (36.0 mg, 0.07 mmol) in DCM (1 mL) and DMSO (6 mL) was added 4 N aqueous NaOH (1.0 mL, 4.0 mmol) and H₂O₂ (0.40 mL, 35% in water). The mixture was stirred for 30 min at room temperature, diluted with water, and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 65% EtOAc in hexanes) to yield 4-(5-(5-(*tert*-butyl)-2-methylphenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)benzamide. ¹H NMR (400 MHz, CDCl₃): δ 7.65 (dd, *J* = 8.0, 8.4 Hz, 2H), 7.12–7.24 (m, 5H), 7.05 (dd, *J* = 8.0, 2.0 Hz, 1H), 6.81 (d, *J* = 7.2 Hz, 1H), 6.70 (d, *J* = 8.4 Hz, 1H), 6.05 (br s, 1H), 5.73 (br s, 1H) 4.11 (m, 2H), 3.56 (m, 2H), 3.36 (m, 2H), 3.01 (m,

2H), 2.31 (s, 3H), 2.09 (s, 3H), 1.86 (m, 1H), 1.31 (s, 9H), 0.81 (m, 6H). MS: (ES) m/z calculated for $C_{35}H_{43}N_4O_2$ $[M + H]^+$ 551.3, found 551.3.

Example 3

- 5 **Synthesis of 1-(4-(5-(3,5-dichloropyridin-2-yl)-2-(2,6-dimethylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-difluorophenyl)urea**



[0131] Step a: To a mixture of 2,5-difluoro-4-nitrobenzoic acid (35.5 g, 174.8 mmol) in dichloromethane (400 mL) at room temperature, was added slowly oxalyl chloride (16.0 mL, 186.3 mmol), followed by the addition of DMF (0.2 mL, 2.6 mmol). The resulting mixture was stirred at room temperature overnight. It was then concentrated *in vacuo* to yield 2,5-difluoro-4-nitrobenzoyl chloride and used directly for next step.

[0132] Step b: To a mixture of *tert*-butyl 4-oxopiperidine-1-carboxylate (35.6 g, 175.8 mmol) in dichloromethane (500 mL) at 0 °C was added MgCl₂ (34.0 g, 357.1 mmol), 2,5-difluoro-4-nitrobenzoyl chloride (38.8 g, 175.1 mmol) and triethylamine (50.0 mL, 355.8 mmol) sequentially. The mixture was stirred for 30 min at 0 °C followed by 7 h at room temperature. It was then cooled to 0 °C, quenched with saturated aqueous NH₄Cl and extracted with dichloromethane. The organic layer was separated, washed with brine, dried over Na₂SO₄ and filtered. The solvent was concentrated under reduced pressure to afford *tert*-butyl 3-(2,5-difluoro-4-nitrobenzoyl)-4-oxopiperidine-1-carboxylate. MS: (ES) *m/z* calculated for C₁₇H₁₉F₂N₂O₆Na [M + Na]⁺ 385.1, found 385.1.

[0133] Step c: A mixture of *tert*-butyl 3-(2,5-difluoro-4-nitrobenzoyl)-4-oxopiperidine-1-carboxylate (30.0 g, 78.1 mmol) and (2,6-dimethylphenyl)hydrazine hydrochloride (17.5 g, 101.5 mmol) in EtOH (30 mL) was heated to 75 °C for 4 h. The mixture was then cooled to room temperature, concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 30% EtOAc in hexanes) to give *tert*-butyl 3-(2,5-difluoro-4-nitrophenyl)-2-(2,6-dimethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₅H₂₆F₂N₄O₄ [M + H]⁺ 485.2, found 485.2.

[0134] Step d: A mixture of *tert*-butyl 3-(2,5-difluoro-4-nitrophenyl)-2-(2,6-dimethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (10.0 g, 20.6 mmol) and PtO₂ (0.5 g, 2.2 mmol) in EtOAc (100 mL) was agitated in a Parr shaker bottle under hydrogen at 40 psi overnight. The mixture was filtered through Celite and concentrated *in vacuo* to afford *tert*-butyl 3-(4-amino-2,5-difluorophenyl)-2-(2,6-dimethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₅H₂₈F₂N₄O₂ [M + H]⁺ 455.2, found 455.2.

[0135] Step e: A mixture of 3-(4-amino-2,5-difluorophenyl)-2-(2,6-dimethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (7.9 g, 17.3 mmol) and benzoyl isocyanate (2.6 g, 17.3 mmol) in THF (40 mL) was stirred for 3 h at room temperature. The mixture was concentrated under reduced pressure to obtain *tert*-butyl 3-(4-(3-benzoylureido)-2,5-difluorophenyl)-2-(2,6-dimethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate.


[0136] A mixture of *tert*-butyl 3-(4-(3-benzoylureido)-2,5-difluorophenyl)-2-(2,6-dimethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (~17.3 mmol, from above) and K₂CO₃ (7.1 g, 51.3 mmol) in MeOH (100 mL) was stirred for 2 h at room temperature followed by 20 min at 50 °C. The mixture was extracted with IPA:CHCl₃ (1:3). The organic layer was separated, dried over Na₂SO₄, concentrated under reduced pressure and purified by silica gel flash chromatography (0 to 70% EtOAc in hexanes) to afford *tert*-butyl 3-(2,5-difluoro-4-ureidophenyl)-2-(2,6-dimethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₆H₂₉F₂N₅O₃ [M + H]⁺ 498.2, found 498.2

[0137] Step f: A mixture of *tert*-butyl 3-(2,5-difluoro-4-ureidophenyl)-2-(2,6-dimethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (7.0 g, 14.1 mmol) and 4 N HCl in dioxane (14.0 mL, 56.0 mmol) in dichloromethane (20 mL) was stirred at room temperature overnight. The mixture was then concentrated *in vacuo* to yield 1-(4-(2-(2,6-dimethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea hydrochloride. MS: (ES) *m/z* calculated for C₂₁H₂₁F₂N₅O [M + H]⁺ 398.2, found 398.2.

[0138] Step g: Triethylamine (3.9 mL, 27.7 mmol) was added to a suspension of 1-(4-(2-(2,6-dimethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea hydrochloride (4 g, 9.23 mmol), 3,5-dichloro-2-fluoropyridine (1.7 g, 10.2 mmol), and Li₂CO₃ (2.0 g, 27.7 mmol) in DMSO (14 mL) under magnetic stirring. The resulting mixture was stirred at 90 °C for 4 h. After cooling to room temperature, the reaction mixture was diluted with DCM, washed with brine, and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (20% to 50% EtOAc in hexanes, followed by 0% to 50% EtOAc in dichloromethane) followed by recrystallization in MeOH/dichloromethane /EtOAc to afford 1-(4-(5-(3,5-dichloropyridin-2-yl)-2-(2,6-dimethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea. ¹H NMR (400 MHz, CD₃OD): δ 8.16 (d, *J* = 2.3 Hz, 1H), 8.01 (dd, *J* = 6.6, 12.5 Hz, 1H), 7.83 (d, *J* = 2.3 Hz, 1H), 7.25 (dd, *J* = 7.0, 8.2 Hz, 1H), 7.06–7.16 (m, 2H), 6.70 (dd, *J* = 6.6, 11.4 Hz, 1H), 4.86 (br, 3H), 4.37 (s, 2H), 3.76 (t, *J* = 5.8 Hz, 2H), 3.03 (t, *J* = 5.8 Hz, 2H), 1.99 (s, 6H). MS: (ES) *m/z* calculated C₂₆H₂₃Cl₂F₂N₆O [M + H]⁺ 543.1, found 543.1.

30

Example 4

Synthesis of 1-(4-(2-(2,6-diethylphenyl)-5-(*tert*-pentyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea

5 *Caution: Diazonium formation could be potentially dangerous, please handle with care and wear proper personal protection equipment!*

[0139] Step a: To a 250 mL flask charged with 90 mL of concentrated hydrochloric acid under magnetic stirring was added 2,6-diethylaniline (10.0 g, 67 mmol). The resulting mixture was stirred for 30 min and cooled with an ice-salt bath until the internal temperature reached $-5\text{ }^{\circ}\text{C}$. A solution of sodium nitrite (5.5 g, 80 mmol) in water (60 mL) was added slowly to the above mixture while maintaining the internal temperature below $5\text{ }^{\circ}\text{C}$.

[0140] Separately, tin(II) chloride dihydrate (31.6 g, 140 mmol) was added to a 500 mL 3-neck round bottom flask charged with concentrated hydrochloric acid (60 mL) under mechanical stirring. The resulting solution was then cooled with an ice bath.

[0141] The diazonium slurry was then filtered into the 500 mL flask containing the cooled tin chloride solution with vigorous stirring. After 90 min, the reaction mixture was transferred to a 500 mL Erlenmeyer flask and the flask was rinsed with water (20 mL) and chloroform (8 mL). The combined mixture was stirred overnight at room temperature. The entire liquid layer was decanted to give a wet solid. The recovered material was dried *in vacuo* for one day and then transferred to a 500 mL 3-neck round bottom flask equipped with an overhead mechanical stirrer and stirred with ether (180 mL). The resulting mixture was cooled in an ice bath, and NaOH solution (10 N, 30 mL) was added slowly to the above mixture while maintaining the inner temperature below $12\text{ }^{\circ}\text{C}$. After the addition, the mixture was allowed to stand for 2 h on ice. The ether layer was decanted into a 500 mL flask and a stream of hydrogen chloride gas was bubbled into the ether solution while stirring. The resulting precipitate was collected by filtration to afford (2,6-diethylphenyl)hydrazine hydrochloride. MS: (ES) *m/z* calculated for $\text{C}_{10}\text{H}_{17}\text{N}_2$ $[\text{M} + \text{H}]^+$ 165.1, found 165.1.

[0142] Step b: A mixture of *tert*-butyl 3-(2,5-difluoro-4-nitrobenzoyl)-4-oxopiperidine-1-carboxylate (60.0 g, 156.1 mmol) and (2,6-diethylphenyl)hydrazine hydrochloride (30.0 g, 149.5 mmol) in EtOH (560 mL) was heated to $50\text{ }^{\circ}\text{C}$ for 3 h. The mixture was then cooled to room temperature and quenched with saturated aqueous NaHCO_3 . The mixture was extracted with EtOAc, the organic layer was separated, washed with brine, dried over Na_2SO_4 and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 50% EtOAc in hexanes) to afford *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for $\text{C}_{27}\text{H}_{31}\text{F}_2\text{N}_4\text{O}_4$ $[\text{M} + \text{H}]^+$ 513.2, found 513.5.

[0143] Step c: A mixture of *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (9.6 g, 18.7 mmol), iron powder (10.0 g, 179.1 mmol) and NH₄Cl (15.0 g, 280.4 mmol) in EtOH (200 mL) and water (20 mL) was heated to 80 °C for 1 h. The mixture was then cooled to room temperature, filtered over
5 Celite and washed with EtOAc. The filtrate was partitioned between EtOAc and saturated aqueous NaHCO₃. The organic layer was separated, dried over Na₂SO₄ and filtered. The solvent was concentrated *in vacuo* to afford *tert*-butyl 3-(4-amino-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₇H₃₃F₂N₄O₂ [M + H]⁺ 483.3, found 483.3.

10 [0144] Step d: A mixture of *tert*-butyl 3-(4-amino-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (9.2 g, 19.1 mmol) and benzoyl isocyanate (11.3 g, 76.8 mmol) in THF (100 mL) was stirred at room temperature for 4 h. The mixture was then concentrated *in vacuo* to afford *tert*-butyl 3-(4-(3-benzoylureido)-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-
15 carboxylate.

[0145] A mixture of *tert*-butyl 3-(4-(3-benzoylureido)-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (~19.1 mmol) from above and K₂CO₃ (10.0 g, 72.3 mmol) in MeOH (100 mL) was stirred for 7 h at room
20 temperature. The reaction mixture was extracted with IPA:CHCl₃ (1:3). The organic layer was separated, dried over Na₂SO₄ and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 100% EtOAc in dichloromethane followed by 0 to 20% MeOH in dichloromethane) to afford *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-ureidophenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₈H₃₄F₂N₅O₃ [M + H]⁺ 526.3, found 526.3.


25 [0146] Step e: A mixture of *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-ureidophenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (2.9 g, 5.5 mmol) and 4 N HCl in dioxane (35.0 mL, 140.0 mmol) in dichloromethane (30 mL) was stirred at room temperature for 1.5 h. The mixture was then concentrated *in vacuo* to yield 1-(4-(2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea hydrochloride. MS: (ES)
30 *m/z* calculated for C₂₃H₂₆F₂N₅O [M + H]⁺ 426.2, found 426.2.

[0147] Step f: To a mixture of 1-(4-(2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea hydrochloride (115.0 mg, 0.3 mmol) in THF (2.5 mL) at 0 °C was added 3-chloro-3-methylbut-1-yne (32 mg, 0.3 mmol), NEt₃ (88 μL, 0.6 mmol) and CuCl (30 mg, 0.3 mmol) sequentially. The mixture was allowed to warm to room temperature and stirred for 30 min. The mixture was then basified with saturated aqueous NaHCO₃ and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 100% EtOAc in hexanes) to afford 1-(4-(2-(2,6-diethylphenyl)-5-(2-methylbut-3-yn-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea. MS: (ES) *m/z* calculated for C₂₈H₃₂F₂N₅O [M + H]⁺ 492.3, found 492.2.

[0148] Step g: A mixture of 1-(4-(2-(2,6-diethylphenyl)-5-(2-methylbut-3-yn-2-yl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea (66.0 mg, 0.13 mmol) and Pd/C (50 mg, 50% in water) in EtOAc (35 mL) was agitated in a Parr shaker bottle under hydrogen at 53psi for 1.5 h. The mixture was filtered over Celite. The filtrate was concentrated under reduced pressure and the residue was purified by HPLC (MeCN/H₂O, with 0.1% TFA), basified with saturated aqueous NaHCO₃ and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, filtered, and treated with 1.0 M HCl in diethyl ether. The solvent was concentrated *in vacuo* to yield 1-(4-(2-(2,6-diethylphenyl)-5-(*tert*-pentyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea as hydrochloride salt. ¹H NMR (400 MHz, CD₃OD): δ 8.15 (br s, 1H), 7.47 (dd, *J* = 7.4, 7.4 Hz, 1H), 7.29 (m, 2H), 6.68 (br s, 1H), 4.57 (br s, 2H), 4.18 (br s, 1H), 3.62 (br s, 1H), 3.32 (br s, 2H), 2.38 (br s, 2H), 2.22 (br s, 2H), 1.98 (br s, 2H), 1.70 (s, 1H), 1.55 (br s, 6H), 1.55 (br s, 6H), 1.32–1.42 (m, 3H), 1.00–1.22 (m, 9H). MS: (ES) *m/z* calculated for C₂₈H₃₆F₂N₅O [M + H]⁺ 496.3, found 496.3.

Example 5

Synthesis of *N*-(4-(5-(2,4-bis(trifluoromethyl)benzyl)-2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)formamide



[0149] Step a: A mixture of *tert*-butyl 3-(4-amino-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (1.7 g, 3.5 mmol), acetyl chloride (1.4 mL, 19.6 mmol) and NEt₃ (3.7 mL, 26.1 mmol) in THF (120 mL) was stirred at room temperature for 2 h. The reaction mixture was quenched with saturated aqueous NaHCO₃ and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄ and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 80% EtOAc in hexanes) to afford *tert*-butyl 3-(4-acetamido-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₉H₃₅F₂N₄O₃ [M + H]⁺ 525.3, found 525.6.

[0150] Step b: A mixture of *tert*-butyl 3-(4-acetamido-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (1.3 g, 2.4 mmol) and 4 N HCl in dioxane (20.0 mL, 80.0 mmol) in dichloromethane (20 mL) was stirred at room temperature for 0.5 h. The mixture was then concentrated *in vacuo* to yield *N*-(4-(2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)acetamide hydrochloride. MS: (ES) *m/z* calculated for C₂₄H₂₇F₂N₄O [M + H]⁺ 425.2, found 425.2.

[0151] Step c: A mixture of *N*-(4-(2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)acetamide hydrochloride (0.45 g, 1.0 mmol), 2,4-*bis*(trifluoromethyl)benzaldehyde (0.7 g, 2.9 mmol), NaBH(OAc)₃ (0.8 g, 3.8 mmol), NEt₃ (0.5 mL, 3.6 mmol) and HOAc (0.2 mL, 3.3 mmol) in dichloromethane (5 mL) was stirred at 30 °C for 1 h. The reaction was quenched with saturated aqueous NaHCO₃ and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 80% EtOAc in hexanes) to afford *N*-(4-(5-(2,4-*bis*(trifluoromethyl)benzyl)-2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)acetamide. MS: (ES) *m/z* calculated for C₃₃H₃₀F₈N₄O [M + H]⁺ 651.3, found 651.6.

[0152] Step d: A mixture of *N*-(4-(5-(2,4-*bis*(trifluoromethyl)benzyl)-2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)acetamide (0.5 g, 0.8 mmol) and 4 N HCl in dioxane (3.0 mL, 12.0 mmol) in water (0.6 mL) was stirred at 80 °C for 40 min. The mixture was cooled to room temperature, basified with saturated aqueous NaHCO₃ and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 70% EtOAc in hexanes) to afford 4-(5-(2,4-*bis*(trifluoromethyl)benzyl)-2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluoroaniline. MS: (ES) *m/z* calculated for C₃₁H₂₉F₈N₄ [M + H]⁺ 609.2, found 609.2.


[0153] Step e: A mixture of 4-(5-(2,4-*bis*(trifluoromethyl)benzyl)-2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluoroaniline (25.0 mg, 0.04 mmol) and HCO₂H (1 mL) was stirred at 75 °C for 40 min. The mixture was cooled to room temperature, basified with saturated aqueous NaHCO₃ and extracted with EtOAc. The organic

layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 70% EtOAc in hexanes) to afford *N*-(4-(5-(2,4-bis(trifluoromethyl)benzyl)-2-(2,6-diethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)formamide. ¹H NMR (400 MHz, CDCl₃): δ 8.38 (d, *J* = 1.2 Hz, 1H), 8.15 (m, 2H), 7.89 (br s, 1H), 7.79 (d, *J* = 8.4 Hz, 1H), 7.53 (br s, 1H), 7.28 (dd, *J* = 7.6, 7.6 Hz, 1H), 7.10 (d, *J* = 7.6 Hz, 2H), 6.55 (m, 1H), 3.95 (s, br, 2H), 3.58 (bs, 2H), 2.93 (m, 4H), 2.31 (sextet, *J* = 7.6 Hz, 2H), 2.19 (sextet, *J* = 7.2 Hz, 2H), 1.08 (t, *J* = 7.4 Hz, 6H). MS: (ES) *m/z* calculated for C₃₂H₂₉F₈N₄O [M + H]⁺ 637.2, found 637.2.

10

Example 6

Synthesis of 1-(4-(2-(2,6-diethylphenyl)-5-(2-hydroxy-2-methyl-1-phenylpropyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea



[0154] Step a: A mixture of *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (1.0 g, 2.0 mmol) and 4 N HCl in dioxane (5.0 mL, 20.0 mmol) in dichloromethane (10 mL) was stirred at room temperature for 1.5 h. The mixture was then concentrated *in vacuo* to yield 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridine hydrochloride. MS: (ES) *m/z* calculated for C₂₂H₂₃F₂N₄O₂ [M + H]⁺ 413.2, found 413.2.

[0155] *N,N*-diisopropylethylamine (3.0 mL, 17.3 mmol) was added to a suspension of the above 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridine hydrochloride (~2.0 mmol), and ethyl 2-bromo-2-phenylacetate (2.0 mL, 11.4 mmol) in acetonitrile (6 mL) under magnetic stirring. The resulting mixture was stirred at 90 °C for 3 h.

After cooling to room temperature, the reaction mixture was diluted with EtOAc, washed with brine and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (10% to 30% EtOAc in hexanes) to afford ethyl 2-(2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-
5 c]pyridin-5-yl)-2-phenylacetate. MS: (ES) *m/z* calculated for C₃₂H₃₃F₂N₄O₄ [M + Na]⁺ 575.2, found 575.3.

[0156] Step b: A mixture of ethyl 2-(2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-*c*]pyridin-5-yl)-2-phenylacetate (1.0 g, 1.7 mmol), iron powder (1.0 g, 17.9 mmol) and NH₄Cl (1.5 g, 26.9 mmol) in EtOH (20 mL) and water (2 mL)
10 was heated to 80 °C for 1 h. The mixture was then cooled to room temperature, filtered over Celite and washed with EtOAc. The filtrate was partitioned between EtOAc and saturated aqueous NaHCO₃. The organic layer was separated, dried over Na₂SO₄, and filtered. The solvent was concentrated *in vacuo* to afford ethyl 2-(3-(4-amino-2,5-difluorophenyl)-2-(2,6-
diethylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-*c*]pyridin-5-yl)-2-phenylacetate. MS: (ES)
15 *m/z* calculated for C₃₂H₃₅F₂N₄O₂ [M + H]⁺ 545.3, found 545.3.

[0157] Step c: A mixture of ethyl 2-(3-(4-amino-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-*c*]pyridin-5-yl)-2-phenylacetate (800.0 mg, 1.5 mmol) and benzoyl isocyanate (1.1 g, 7.7 mmol) in THF (10 mL) was stirred at room temperature for 4 h. The mixture was then concentrated *in vacuo* to afford ethyl 2-(3-(4-(3-benzoylureido)-2,5-
20 difluorophenyl)-2-(2,6-diethylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-*c*]pyridin-5-yl)-2-phenylacetate.


[0158] A mixture of ethyl 2-(3-(4-(3-benzoylureido)-2,5-difluorophenyl)-2-(2,6-
diethylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-*c*]pyridin-5-yl)-2-phenylacetate (~1.5 mmol)
25 from above and K₂CO₃ (1.0 g, 7.2 mmol) in MeOH (10 mL) was stirred at room temperature overnight. The reaction mixture was extracted with EtOAc. The organic layer was separated, dried over Na₂SO₄ and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (10 to 45% EtOAc in hexanes) to afford ethyl 2-(2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-ureidophenyl)-2,4,6,7-tetrahydro-5H-
pyrazolo[4,3-*c*]pyridin-5-yl)-2-phenylacetate. MS: (ES) *m/z* calculated for C₃₃H₃₆F₂N₅O₃ [M +
30 H]⁺ 588.3, found 588.3.

[0159] Step d: To a solution of ethyl 2-(2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-ureidophenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridin-5-yl)-2-phenylacetate (100.0 mg, 0.2 mmol) in THF (5 mL) was added 1.6 M CH₃Li solution in diethyl ether (0.7 mL, 1.1 mmol) at 0 °C. The obtained mixture was stirred at the same temperature for 30 min, quenched with saturated NH₄Cl and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was removed under reduced pressure and the residue was purified by preparative TLC (40% EtOAc in hexanes followed by 30% EtOAc in dichloromethane) to afford 1-(4-(2-(2,6-diethylphenyl)-5-(2-hydroxy-2-methyl-1-phenylpropyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea. ¹H NMR (400 MHz, CD₃OD): δ 7.93 (dd, *J* = 6.6, 12.4 Hz, 1H), 7.10-7.50 (m, 8H), 6.54 (dd, *J* = 6.6, 11.6 Hz, 1H), 4.86 (br, 3H), 3.41-3.67 (m, 4H), 2.63-2.92 (m, 3H), 2.02-2.32 (m, 4H), 1.32 (s, 3H), 1.28 (br s, 1H), 1.16 (s, 3H), 1.10 (t, *J* = 7.8 Hz, 3H), 1.01 (t, *J* = 7.8 Hz, 3H). MS: (ES) *m/z* calculated for C₃₃H₃₈F₂N₅O₂ [M + H]⁺ 574.3, found 574.5.

15

Example 7

Synthesis of 1-(4-(5-(2,4-bis(trifluoromethyl)benzyl)-2-(2,6-diethylphenyl)-6,6-dimethyl-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea



[0160] Step a: To a mixture of *tert*-butyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate (4.0 g, 17.6 mmol) in DCM (50 mL) at 0 °C was added MgCl_2 (3.4 g, 35.2 mmol), 2,5-difluoro-4-nitrobenzoyl chloride (4.3 g, 19.4 mmol) and triethylamine (4.9 mL, 35.2 mmol) sequentially.

- 5 The mixture was stirred for 30 min at 0 °C followed by 1.5 h at room temperature. The mixture was then cooled to 0 °C, quenched with saturated aqueous NH_4Cl and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na_2SO_4 , and filtered. The

solvent was concentrated under reduced pressure to afford *tert*-butyl 5-(2,5-difluoro-4-nitrobenzoyl)-3,3-dimethyl-4-oxopiperidine-1-carboxylate. MS: (ES) *m/z* calculated for C₁₉H₂₂F₂N₂O₆Na [M + Na]⁺ 435.1, found 435.1.

[0161] Step b: A mixture of *tert*-butyl 5-(2,5-difluoro-4-nitrobenzoyl)-3,3-dimethyl-4-oxopiperidine-1-carboxylate (~17.6 mmol, crude from step a), (2,6-diethylphenyl)hydrazine hydrochloride (3.5 g, 17.6 mmol) and pyridine (2.1 mL, 26.4 mmol) in MeOH (100 mL) was heated to 45 °C overnight. The mixture was cooled to room temperature and water was added. The mixture was extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 60% EtOAc in hexanes) to afford *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-6,6-dimethyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₉H₃₅F₂N₄O₄ [M + H]⁺ 541.3, found 541.6.

[0162] Step c: A mixture of *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-nitrophenyl)-6,6-dimethyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (6.7 g, 6.2 mmol), iron powder (12.0 g, 214.9 mmol) and NH₄Cl (40.0 g, 742.1 mmol) in EtOH (100 mL) and water (10 mL) was heated to 90 °C for 30 min. The mixture was cooled to room temperature, filtered over Celite and washed with EtOAc. The filtrate was partitioned between EtOAc and saturated aqueous NaHCO₃. The organic layer was separated, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 80% EtOAc in hexanes, then 0 to 30% EtOAc in dichloromethane) to afford *tert*-butyl 3-(4-amino-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-6,6-dimethyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₉H₃₇F₂N₄O₂ [M + H]⁺ 511.3, found 511.6.

[0163] Step d: A mixture of *tert*-butyl 3-(4-amino-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-6,6-dimethyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (1.0 g, 2.0 mmol) and benzoyl isocyanate (0.5 g, 3.4 mmol) in THF (6 mL) was stirred at room temperature for 1 h. The mixture was concentrated on a rotary evaporator under reduced pressure to obtain *tert*-butyl 3-(4-(3-benzoylureido)-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-6,6-dimethyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate.

[0164] A mixture of *tert*-butyl 3-(4-(3-benzoylureido)-2,5-difluorophenyl)-2-(2,6-diethylphenyl)-6,6-dimethyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (~2.0 mmol) from above and K₂CO₃ (1.0 g, 7.2 mmol) in MeOH (20 mL) was stirred for 2 h at room temperature. The mixture was extracted with IPA:CHCl₃ (1:3). The organic layer was
5 separated, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to 80% EtOAc in dichloromethane) to afford *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-ureidophenyl)-6,6-dimethyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₃₀H₃₈F₂N₅O₃ [M + H]⁺ 554.3, found 554.2


10 [0165] Step e: A mixture of *tert*-butyl 2-(2,6-diethylphenyl)-3-(2,5-difluoro-4-ureidophenyl)-6,6-dimethyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (0.6 g, 1.1 mmol) and 4 N HCl in dioxane (30.0 mL, 120.0 mmol) in dichloromethane (10 mL) was stirred at room temperature for 1.5 h. The mixture was concentrated under reduced pressure to obtain 1-(4-(2-(2,6-diethylphenyl)-6,6-dimethyl-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea hydrochloride. MS: (ES) *m/z* calculated for C₂₅H₃₀F₂N₅O [M + H]⁺ 454.2,
15 found 454.2.

[0166] Step f: To a mixture of 1-(4-(2-(2,6-diethylphenyl)-6,6-dimethyl-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea hydrochloride (100.0 mg, 0.2 mmol), 2,4-*bis*(trifluoromethyl)benzaldehyde (100.0 mg, 0.8 mmol), and *N,N*-diisopropylethylamine (0.3
20 mL, 1.7 mmol) in dichloroethane (10 mL) under magnetic stirring was added NaBH(OAc)₃ (250.0 mg, 1.2 mmol) followed by AcOH (two drops). The resulting mixture was stirred at 45 °C for 3 h. After cooling to room temperature, the reaction mixture was quenched with MeOH, diluted with EtOAc, washed with brine, and dried over MgSO₄. The solvent was removed under reduced pressure and the residue was purified by preparative TLC (50% EtOAc in hexanes),
25 followed by HPLC (MeCN/H₂O, with 0.1% TFA) to afford 1-(4-(5-(2,4-*bis*(trifluoromethyl)benzyl)-2-(2,6-diethylphenyl)-6,6-dimethyl-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2,5-difluorophenyl)urea. ¹H NMR (400 MHz, CD₃OD): δ 8.30 (d, *J* = 8.2 Hz, 1H), 7.83–7.95 (m, 3H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.20 (d, *J* = 7.7 Hz, 2H), 6.50 (dd, *J* = 6.5, 11.6 Hz, 1H), 4.87 (br, 3H), 4.00 (s, 2H), 3.57 (s, 2H), 2.79 (s, 2H), 2.22–2.78 (m, 4H),

1.35 (s, 6H), 1.08 (t, $J = 7.8$ Hz, 6H). MS: (ES) m/z calculated $C_{34}H_{34}F_8N_5O$ $[M + H]^+$ 680.3, found 680.6.

Example 8


5 Synthesis of 1-(4-(2-(2,6-diethylphenyl)-5-isobutyryl-6,6-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-difluorophenyl)urea



[0167] A mixture of 1-(4-(2-(2,6-diethylphenyl)-6,6-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-difluorophenyl)urea hydrochloride (25 mg, 0.05 mmol),
 10 isobutyric acid (80.0 mg, 1.1 mmol), HATU (100 mg, 0.26 mmol) and NEt_3 (0.1 mL, 0.71 mmol) in DMF (1.5 mL) was stirred at 50–70 °C for 40 min. The mixture was cooled to room temperature, basified with saturated aqueous $NaHCO_3$, and extracted with EtOAc. The organic layer was separated, washed with brine, dried over Na_2SO_4 , and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash
 15 chromatography (0 to 100% EtOAc in hexanes) to afford 1-(4-(2-(2,6-diethylphenyl)-5-isobutyryl-6,6-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-2,5-difluorophenyl)urea. 1H NMR (400 MHz, $CDCl_3$): δ 8.06 (m, 1H), 7.38 (dd, $J = 7.6, 7.6$ Hz, 1H), 7.21 (d, $J = 8.0$ Hz, 2H), 6.55 (m, 1H), 4.58 (s, 2H), 3.30 (m, 3H), 2.95 (s, 2H), 2.92 (m, 1H), 2.24 (q, $J = 7.6$ Hz, 4H), 1.58 (s, 6H), 1.04 (m, 12H). MS: (ES) m/z calculated for
 20 $C_{29}H_{36}F_2N_5O_2$ $[M + H]^+$ 524.3, found 524.6.

Example 9

Synthesis of 1-(4-(5-(2-chloro-4-(trifluoromethyl)-phenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-2-fluorophenyl)urea



[0168] Step a: To a stirred solution of *tert*-butyl 4-oxopiperidine-1-carboxylate (5.0 g, 25.1 mmol) in anhydrous THF (30 mL) at $-78\text{ }^\circ\text{C}$ under N_2 atmosphere was added 1.0 M LiHMDS solution in THF (27.5 mL, 27.5 mmol) dropwise. After the solution was stirred for 30 min, a solution of 3-fluoro-4-nitrobenzoyl chloride (5.1 g, 25.1 mmol) in THF (6 mL) was added to the

mixture. The reaction mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 1 h, and then warmed to room temperature and stirred for 2 h. After completion, the reaction mixture was quenched with 1 M NaHSO_4 (50 mL), stirred for 10 min, then diluted with EtOAc. The organic layer was washed with H_2O , brine, dried over Na_2SO_4 , and filtered. The solvent was concentrated *in vacuo*, and the
5 crude material was used directly for the next step without further purification.

[0169] Step b: To a stirred solution of *tert*-butyl 3-(3-fluoro-4-nitrobenzoyl)-4-oxopiperidine-1-carboxylate (6.0 g, 16.4 mmol) in EtOH (120 mL) and glacial acetic acid (12.0 mL, 207.9 mmol) was added (2-isobutoxy-6-methylphenyl)hydrazine hydrochloride (3.8 g, 16.4 mmol) at room temperature. The mixture was stirred for 15 min and then refluxed for 3 h. After
10 completion of the reaction, solvent was removed under reduced pressure and the residue diluted with EtOAc (100 mL). The organic layer was washed with aqueous 2 N NaOH, brine, dried over Na_2SO_4 , and filtered. The solvent was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (5 to 20% dichloromethane in MeOH) to give *tert*-butyl 3-(3-fluoro-4-nitrophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-
15 pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for $\text{C}_{28}\text{H}_{34}\text{FN}_4\text{O}_5$ [$\text{M} + \text{H}$]⁺ 525.2, found 525.3

[0170] Step c: To a solution of *tert*-butyl 3-(3-fluoro-4-nitrophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (0.8 g, 1.5 mmol) in methanol (20 mL) was added 10% Pd/C (250 mg) at room temperature. The resulting mixture
20 was stirred under a hydrogen (30 psi) atmosphere for 1 h. The reaction mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to give *tert*-butyl 3-(4-amino-3-fluorophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate, which was used directly in the next step without further purification.

[0171] Step d: To the solution of *tert*-butyl 3-(4-amino-3-fluorophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate from the previous
25 step (0.7 g, 1.4 mmol) in anhydrous THF (10 mL), was added K_2CO_3 (0.8 g 5.7 mmol) and acetyl chloride (0.4 g, 5.1 mmol) at room temperature. The reaction mixture was stirred at room temperature for 4 h then diluted with water. The mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered, and evaporated *in*

vacuo to give *tert*-butyl-3-(4-acetamido-3-fluorophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate.

[0172] Step e: To a solution of *tert*-butyl 3-(4-acetamido-3-fluorophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (0.8 g, 1.5 mmol) in dichloromethane (10 mL) was added TFA (0.4 g, 3.6 mmol). The resulting mixture was stirred at room temperature for 2 h. After completion of the reaction, the solvent was diluted with water and saturated aqueous NaHCO₃ and extracted with dichloromethane. The organic layer was washed with brine and dried over Na₂SO₄. The solvent was removed under reduced pressure to give *N*-(2-fluoro-4-(2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)phenyl)acetamide. MS: (ES) *m/z* calculated for C₂₅H₃₀FN₄O₂ [M + H]⁺ 437.2, found 437.3.

[0173] Step f: To a mixture of *N*-(2-fluoro-4-(2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)phenyl)acetamide (100.0 mg, 0.25 mmol), 1-bromo-2-chloro-4-(trifluoromethyl)benzene (85.0 mg, 0.37 mmol), NaO*t*Bu (47.0 mg, 0.49 mmol) and BINAP (80.0 mg, 0.05 mmol) in toluene (3 mL) was added Pd₂(dba)₃ (22 mg, 0.02 mmol). The reaction mixture was degassed (N₂) for 5 min and stirred under N₂ at 105 °C for 6 h. After completion of the reaction, the mixture was cooled to room temperature, diluted with EtOAc, and filtered through Celite. The filtrate was washed with brine, and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% EtOAc in hexanes) to give *N*-(4-(5-(2-chloro-4-(trifluoromethyl)phenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2-fluorophenyl)acetamide. MS: (ES) *m/z* calculated for C₃₂H₃₂ClF₄N₄O₂ [M + H]⁺ 615.2, found 615.3.

[0174] Step g: To a solution of *N*-(4-(5-(2-chloro-4-(trifluoromethyl)phenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2-fluorophenyl)acetamide (100.0 mg, 0.4 mmol) in MeOH (3 mL) was added 4 N HCl in dioxane (2.5 mL, 10.0 mmol). The resulting mixture was stirred at room temperature for 2 h. After completion of the reaction, the mixture was diluted with saturated aqueous NaHCO₃ and extracted with dichloromethane. The combined organic layer was washed with brine, and dried over Na₂SO₄. The solvent was removed under reduced pressure to give 4-(5-(2-chloro-4-(trifluoromethyl)phenyl)-2-(2-


isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2-fluoroaniline. MS: (ES) *m/z* calculated for C₃₀H₃₀ClF₄N₄O [M + H]⁺ 573.2, found 573.2.

[0175] Step h: To a stirred solution of 4-(5-(2-chloro-4-(trifluoromethyl)phenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2-fluoroaniline (75.0 mg, 0.13 mmol) in anhydrous THF (5 mL) was added *N,N*-disopropylethylamine (75.0 mg, 0.65 mmol) and trimethylisocyanate (140.0 mg, 1.2 mmol). The reaction mixture was stirred at room temperature for 16 h. After completion, the reaction mixture was diluted with EtOAc, washed with brine, and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue was purified by silica gel flash chromatography (20 to 60% EtOAc in hexanes) to afford 1-(4-(5-(2-chloro-4-(trifluoromethyl)phenyl)-2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)-2-fluorophenyl)urea. ¹H NMR (400 MHz, CD₃OD): δ 8.00 (t, *J* = 8.6 Hz, 1H), 7.69 (d, *J* = 2.0 Hz, 1H), 7.54 (d, *J* = 8.6 Hz, 1H), 7.39 (d, *J* = 8.2 Hz, 1H), 7.33 (t, *J* = 7.8 Hz, 1H), 7.0 (d, *J* = 8.2 Hz, 1H), 6.80–6.95 (m, 3H), 4.87 (br, 3H), 4.32 (q, *J* = 9.4 Hz, 2H), 3.65–3.75 (m, 2H), 3.61 (t, *J* = 5.8 Hz, 2H), 2.95–3.10 (m, 2H), 2.01 (s, 3H), 1.85–1.98 (m, 1H), 0.86 (d, *J* = 6.6 Hz, 6H). MS: (ES) *m/z* calculated for C₃₁H₃₁ClF₄N₅O₂ [M + H]⁺ 616.2, found 616.2.

Example 10

Synthesis of 1-(2-fluoro-4-(2-(2-isobutoxy-6-methylphenyl)-5-((2-(trifluoromethyl)phenyl)sulfonyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-

yl)phenyl)urea




[0176] Step a: A mixture of *tert*-butyl 3-(4-amino-3-fluorophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (2.4 g, 4.9 mmol),
 5 isocyanatotrimethylsilane (7.5 g, 65.6 mmol) and acetic acid (2.87 mL, 47.8 mmol) in dichloromethane (60 mL) was stirred at room temperature for 8 h. The mixture was then basified with saturated aqueous NaHCO₃ and extracted with dichloromethane. The organic layer was separated, washed with brine, dried over Na₂SO₄, and filtered. The solvent was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography (0 to
 10 100% EtOAc in hexanes) to yield *tert*-butyl 3-(3-fluoro-4-ureidophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₉H₃₇FN₅O₄ [M + H]⁺ 538.3, found 538.3.

[0177] Step b: A mixture of *tert*-butyl 3-(3-fluoro-4-ureidophenyl)-2-(2-isobutoxy-6-methylphenyl)-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (1.8 g, 3.3 mmol)
 15 and 4 N HCl in dioxane (17.0 mL, 68.0 mmol) in dichloromethane (20 mL) was stirred at room temperature for 1 h. The mixture was then concentrated *in vacuo* to yield 1-(2-fluoro-4-(2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)urea hydrochloride. MS: (ES) *m/z* calculated for C₂₄H₂₉FN₅O₂ [M + H]⁺ 438.2, found 438.3

[0178] Step c: A mixture of 1-(2-fluoro-4-(2-(2-isobutoxy-6-methylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)phenyl)urea hydrochloride (25.0 mg, 0.05 mmol), 2-(trifluoromethyl)benzenesulfonyl chloride (30.0 mg, 0.12 mmol) and NEt₃ (0.1 mL, 0.7 mmol) in dichloromethane (1.5 mL) was stirred for 30 min at room temperature. The mixture was
5 quenched with water. The obtained mixture was purified by silica gel flash chromatography (0 to 100% EtOAc in hexanes) to yield 1-(2-fluoro-4-(2-(2-isobutoxy-6-methylphenyl)-5-((2-(trifluoromethyl)phenyl)sulfonyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)phenyl)urea. ¹H NMR (400 MHz, CDCl₃): δ 8.17 (m, 1H), 7.97 (dd, *J* = 8.4, 8.4 Hz, 1H), 7.89 (m, 1H), 7.70 (m, 2H), 7.18 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.07 (d, *J* = 2.8 Hz, 1H), 6.68-6.84
10 (m, 4H), 4.87 (s, 2H), 4.50 (q, *J* = 13.6 Hz, 2H), 3.73 (m, 2H), 3.58 (d, *J* = 6.8 Hz, 2H), 2.92 (m, 2H), 1.94 (s, 3H), 1.85 (m, 1H), 0.78 (d, *J* = 6.8 Hz, 6H). MS: (ES) *m/z* calculated for C₃₁H₃₂F₄N₅O₄S[M + H]⁺ 646.2, found 646.2.

Example 11

15 **Synthesis of 4-(5-(5-(tert-butyl)-2-methylphenyl)-2-(2,6-dimethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)phenol**



[0179] Step a: To a stirred solution of *tert*-butyl 4-oxopiperidine-1-carboxylate (3.0 g, 15.1 mmol) in anhydrous THF (30 mL) at $-78\text{ }^{\circ}\text{C}$ under N_2 atmosphere was added 1.0 M LiHMDS solution in THF (16.5 mL, 16.5 mmol) dropwise. After the reaction mixture was stirred for 30 min, a solution of 4-methoxy benzoylchloride (2.6 g, 15.1 mmol) in THF (3 mL) was added to the mixture. The reaction mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 1 h, and then the mixture was allowed to warm to room temperature and stirred for 2 h. After completion, the reaction mixture was diluted with EtOH: AcOH (3:1), and (2,6 dimethylphenyl)hydrazine hydrochloride (2.6 g, 15.1 mmol) was added. The mixture was stirred for 30 min, and then at $100\text{ }^{\circ}\text{C}$ for 16 h. After completion of the reaction, the mixture was cooled to room temperature and diluted with EtOAc. The organic layer was washed with H_2O and then brine. The combined organic layer was dried

over Na₂SO₄, filtered and concentrated. The residue was purified by silica gel flash chromatography (5 to 20% EtOAc in hexanes) to give *tert*-butyl-2-(2,6-dimethylphenyl)-3-(4-methoxyphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate. MS: (ES) *m/z* calculated for C₂₆H₃₂N₃O₃ [M + H]⁺ 434.2, found 434.3

5 [0180] Step b: To a solution of *tert*-butyl-2-(2,6-dimethylphenyl)-3-(4-methoxyphenyl)-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-*c*]pyridine-5-carboxylate (3.5 g, 8.1 mmol) in dichloromethane (30 mL) was added TFA (1.8 g, 16.1 mmol). The resulting mixture was stirred at room temperature for 2 h. After completion of the reaction, the solvent was diluted with water and saturated aqueous NaHCO₃ and extracted with dichloromethane. The organic layer was
10 washed with brine, and dried over Na₂SO₄. The solvent was removed *in vacuo* to give 2-(2,6-dimethylphenyl)-3-(4-methoxyphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridine. MS: (ES) *m/z* calculated for C₂₁H₂₄N₃O [M + H]⁺ 334.2, found 334.2.

[0181] Step c: To a mixture of 2-(2,6-dimethylphenyl)-3-(4-methoxyphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridine (500.0 mg, 1.5 mmol), 4-*tert*-butyl-2-bromo-1-
15 methylbenzene (502.0 mg, 2.2 mmol), NaOtBu (280.0 mg, 2.9 mmol) and X-Phos (70.0 mg, 2.2 mmol) in toluene (10 mL) was added Pd(OAc)₂ (17.0 mg, 0.07 mmol). The reaction mixture was degassed (N₂) for 5 min and stirred under N₂ at 110 °C for 16 h. After completion of the reaction, the mixture was cooled to room temperature and diluted with EtOAc then filtered through Celite. The filtrate was washed with brine, and dried over Na₂SO₄. The solvent was
20 removed under reduced pressure and the residue was purified by silica gel flash chromatography (5 to 20% EtOAc in hexanes) to give 5-(5-(*tert*-butyl)-2-methylphenyl)-2-(2,6-dimethylphenyl)-3-(4-methoxyphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridine. ¹H NMR (400 MHz, CD₃OD): δ 7.22 (m, 1H), 7.18 (d, *J* = 1.9 Hz, 1H), 7.13 (bs, 1H), 7.10 (d, *J* = 2.7 Hz, 1H), 7.09 (s, 1H), 7.05–7.07 (m, 2H), 7.0–7.02 (m, 1H), 6.83 (d, *J* = 2.4 Hz, 1H), 6.81 (d, *J* = 2.4 Hz, 1H),
25 4.13 (s, 2H), 3.73 (s, 3H), 3.38 (t, *J* = 5.8 Hz, 2H), 2.89 (t, *J* = 5.8 Hz, 2H), 2.29 (s, 3H), 1.98 (s, 6H), 1.26 (s, 9H). MS: (ES) *m/z* calculated for C₃₂H₃₈N₃O [M + H]⁺ 480.3, found 480.3.

[0182] Step d: To a stirred solution of 5-(5-(*tert*-butyl)-2-methylphenyl)-2-(2,6-dimethylphenyl)-3-(4-methoxyphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridine (400.0 mg, 0.8 mmol) in anhydrous dichloromethane (10 mL) at –78 °C under N₂ atmosphere was
30 added 1.0 M BBr₃ solution in dichloromethane (2.1 mL, 2.1 mmol) dropwise. The reaction

mixture was stirred at -78°C for 1 h, and then warmed to room temperature and stirred for 2 h. After completion, the reaction mixture was quenched with MeOH (2 mL), stirred for 10 min, then diluted with dichloromethane. The organic layer was washed with H_2O and brine. The organic layer was dried over Na_2SO_4 , filtered and concentrated. The residue was purified by silica gel flash chromatography (5 to 25% EtOAc in hexanes) to give 4-(5-(5-(*tert*-butyl)-2-methylphenyl)-2-(2,6-dimethylphenyl)-4,5,6,7-tetrahydro-2*H*-pyrazolo[4,3-*c*]pyridin-3-yl)phenol. ^1H NMR (400 MHz, CD_3OD): δ 7.49 (bs, 1H), 7.25–7.35 (m, 4H), 7.14 (d, $J = 7.4$ Hz, 2H), 6.98 (d, $J = 2.0$ Hz, 1H), 6.96 (d, $J = 2.0$ Hz, 1H), 6.69 (d, $J = 2.4$ Hz, 1H), 6.67 (d, $J = 2.4$ Hz, 1H), 4.69 (bs, 2H), 3.80–3.90 (m, 2H), 3.12 (bt, $J = 7.0$ Hz, 2H), 2.44 (s, 3H), 1.99 (s, 6H), 1.30 (s, 9H). MS: (ES) m/z calculated for $\text{C}_{31}\text{H}_{36}\text{N}_3\text{O}$ $[\text{M} + \text{H}]^+$ 466.3, found 466.3.

Example 12

[0183] This example illustrates the evaluation of the biological activity associated with specific compounds of the invention.

15 MATERIALS AND MEHOTDS

A. Cells

1. C5a receptor expressing cells

a) *U937 Cells*

[0184] U937 cells are a monocytic cell line which express C5aR, and are available from ATCC (VA). These cells were cultured as a suspension in RPMI-1640 medium supplemented with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate, and 10% FBS. Cells were grown under 5% CO_2 /95% air, 100% humidity at 37°C and subcultured twice weekly at 1:6 (cells were cultured at a density range of 1×10^5 to 2×10^6 cells/mL) and harvested at 1×10^6 cells/mL. Prior to assay, cells are treated overnight with 0.5 mM of cyclic AMP (Sigma, OH) and washed once prior to use. cAMP treated U937 cells can be used in C5aR ligand binding and functional assays.

b) *Isolated human neutrophils*

[0185] Optionally, human or murine neutrophils can be used to assay for compound activity. Neutrophils may be isolated from fresh human blood using density separation and centrifugation. Briefly, whole blood is incubated with equal parts 3% dextran and allowed to separate for 45
5 minutes. After separation, the top layer is layered on top of 15 mls of Ficoll (15 mls of Ficoll for every 30 mls of blood suspension) and centrifuged for 30 minutes at 400 x g with no brake. The pellet at the bottom of the tube is then isolated and resuspended into PharmLyse RBC Lysis Buffer (BD Biosciences, San Jose, CA) after which the sample is again centrifuged for 10
10 minutes at 400 x g with brake. The remaining cell pellet is resuspended as appropriate and consists of isolated neutrophils.

B. Assays

1. Inhibition of C5aR ligand binding

[0186] cAMP treated U937 cells expressing C5aR were centrifuged and resuspended in assay buffer (20 mM HEPES pH 7.1, 140 mM NaCl, 1 mM CaCl₂, 5 mM MgCl₂, and with 0.1%
15 bovine serum albumin) to a concentration of 3 x 10⁶ cells/mL. Binding assays were set up as follows. 0.1 mL of cells was added to the assay plates containing 5 µL of the compound, giving a final concentration of ~2-10 µM each compound for screening (or part of a dose response for compound IC₅₀ determinations). Then 0.1 mL of ¹²⁵I labeled C5a (obtained from Perkin Elmer Life Sciences, Boston, MA) diluted in assay buffer to a final concentration of ~50 pM, yielding
20 ~30,000 cpm per well, was added, the plates sealed and incubated for approximately 3 hours at 4°C on a shaker platform. Reactions were aspirated onto GF/B glass filters pre-soaked in 0.3% polyethyleneimine (PEI) solution, on a vacuum cell harvester (Packard Instruments; Meriden, CT). Scintillation fluid (40 µl; Microscint 20, Packard Instruments) was added to each well, the plates were sealed and radioactivity measured in a Topcount scintillation counter (Packard
25 Instruments). Control wells containing either diluent only (for total counts) or excess C5a (1 µg/mL, for non-specific binding) were used to calculate the percent of total inhibition for compound. The computer program Prism from GraphPad, Inc. (San Diego, Ca) was used to calculate IC₅₀ values. IC₅₀ values are those concentrations required to reduce the binding of radiolabeled C5a to the receptor by 50%. (For further descriptions of ligand binding and other

functional assays, see Dairaghi, *et al.*, *J. Biol. Chem.* **274**:21569-21574 (1999), Penfold, *et al.*, *Proc. Natl. Acad. Sci. USA.* **96**:9839-9844 (1999), and Dairaghi, *et al.*, *J. Biol. Chem.* **272**:28206-28209 (1997)).

2. Calcium mobilization

5 [0187] Optionally, compounds may be further assayed for their ability to inhibit calcium flux in cells. To detect the release of intracellular stores of calcium, cells (e.g., cAMP stimulated U937 or neutrophils) are incubated with 3 μ M of INDO-1AM dye (Molecular Probes; Eugene, OR) in cell media for 45 minutes at room temperature and washed with phosphate buffered saline (PBS). After INDO-1AM loading, the cells are resuspended in flux buffer (Hank's

10 balanced salt solution (HBSS) and 1% FBS). Calcium mobilization is measured using a Photon Technology International spectrophotometer (Photon Technology International; New Jersey) with excitation at 350 nm and dual simultaneous recording of fluorescence emission at 400 nm and 490 nm. Relative intracellular calcium levels are expressed as the 400 nm/490 nm emission ratio. Experiments are performed at 37°C with constant mixing in cuvettes each containing 10⁶

15 cells in 2 mL of flux buffer. The chemokine ligands may be used over a range from 1 to 100 nM. The emission ratio is plotted over time (typically 2-3 minutes). Candidate ligand blocking compounds (up to 10 μ M) are added at 10 seconds, followed by chemokines at 60 seconds (*i.e.*, C5a; R&D Systems; Minneapolis, MN) and control chemokine (*i.e.*, SDF-1 α ; R&D Systems; Minneapolis, MN) at 150 seconds.

20 3. Chemotaxis assays

[0188] Optionally, compounds may be further assayed for their ability to inhibit chemotaxis in cells. Chemotaxis assays are performed using 5 μ m pore polycarbonate, polyvinylpyrrolidone-coated filters in 96-well chemotaxis chambers (Neuroprobe; Gaithersburg, MD) using chemotaxis buffer (Hank's balanced salt solution (HBSS) and 1% FBS). C5aR ligands (*i.e.*,

25 C5a, R&D Systems; Minneapolis, MN) are used to evaluate compound mediated inhibition of C5aR mediated migration. Other chemokines (*i.e.*, SDF-1 α ; R&D Systems; Minneapolis, MN) are used as specificity controls. The lower chamber is loaded with 29 μ l of chemokine (*i.e.*, 0.03 nM C5a) and varying amounts of compound; the top chamber contains 100,000 U937 or neutrophil cells in 20 μ l. The chambers are incubated 1.5 hours at 37°C, and the number of cells

in the lower chamber quantified either by direct cell counts in five high powered fields per well or by the CyQuant assay (Molecular Probes), a fluorescent dye method that measures nucleic acid content and microscopic observation.

C. Identification of inhibitors of C5aR

5 1. Assay

[0189] To evaluate small organic molecules that prevent the C5a receptor from binding ligand, an assay was employed that detected radioactive ligand (i.e., C5a) binding to cells expressing C5aR on the cell surface (for example, cAMP stimulated U937 cells or isolated human neutrophils). For compounds that inhibited binding, whether competitive or not, fewer
10 radioactive counts are observed when compared to uninhibited controls.

[0190] Equal numbers of cells were added to each well in the plate. The cells were then incubated with radiolabeled C5a. Unbound ligand was removed by washing the cells, and bound ligand was determined by quantifying radioactive counts. Cells that were incubated without any organic compound gave total counts; non-specific binding was determined by incubating the
15 cells with unlabeled ligand and labeled ligand. Percent inhibition was determined by the equation:

$$\% \text{ inhibition} = (1 - [(\text{sample cpm}) - (\text{nonspecific cpm})] / [(\text{total cpm}) - (\text{nonspecific cpm})]) \times 100.$$

2. Dose Response Curves

[0191] To ascertain a candidate compound's affinity for C5aR as well as confirm its ability to
20 inhibit ligand binding, inhibitory activity was titered over a 1×10^{-10} to 1×10^{-4} M range of compound concentrations. In the assay, the amount of compound was varied; while cell number and ligand concentration were held constant.

D. In Vivo Efficacy Models

[0192] The compounds of interest can be evaluated for potential efficacy in treating a C5a mediated conditions by determining the efficacy of the compound in an animal model. In addition to the models described below, other suitable animal models for studying the compound of interest can be found in Mizuno, M. *et al.*, *Expert Opin. Investig. Drugs* (2005), 14(7), 807-821, which is incorporated herein by reference in its entirety.

1. Models of C5a induced Leukopenia

a) C5a induced Leukopenia in a Human C5aR knock-in Mouse Model

10 [0193] To study the efficacy of compounds of the instant invention in an animal model, a recombinant mouse can be created using standard techniques, wherein the genetic sequence coding for the mouse C5aR is replaced with sequence coding for the human C5aR, to create a hC5aR-KI mouse. In this mouse, administration of hC5a leads to upregulation of adhesion molecules on blood vessel walls which bind blood leukocytes, sequestering them from the blood stream. Animals are administered 20ug/kg of hC5a and 1 minute later leukocytes are quantified in peripheral blood by standard techniques. Pretreatment of mice with varying doses of the present compounds can almost completely block the hC5a induced leukopenia.

b) C5a induced Leukopenia in a Cynomolgus Model

20 [0194] To study the efficacy of compounds of the instant invention in a non-human primate model model, C5a induced leucopenia is studied in a cynomolgus model. In this model administration of hC5a leads to upregulation of adhesion molecules on blood vessel walls which bind blood leukocytes, hence sequestering them from the blood stream. Animals are administered 10ug/kg of hC5a and 1 minute later leukocytes are quantified in peripheral blood.

Mouse model of ANCA induced Vasculitis

25 [0195] On day 0 hC5aR-KI mice are intravenously injected with 50mg/kg purified antibody to myeloperoxidase (Xiao et al, *J. Clin. Invest.* **110**: 955-963 (2002)). Mice are further dosed with oral daily doses of compounds of the invention or vehicle for seven days, then mice are

sacrificed and kidneys collected for histological examination. Analysis of kidney sections can show significantly reduced number and severity of crescentic and necrotic lesions in the glomeruli when compared to vehicle treated animals.

2. Mouse Model of Choroidal Neovascularization

5 [0196] To study the efficacy of compounds of the instant invention in treatment of age related macular degeneration (AMD) the bruch membrane in the eyes of hC5aR-KI mice are ruptured by laser photocoagulation (Nozika et al, *PNAS* **103**: 2328-2333 (2006). Mice are treated with vehicle or a daily oral or appropriate intra-vitreous dose of a compound of the invention for one to two weeks. Repair of laser induced damage and neovascularization are assessed by histology
10 and angiography.

3. Rheumatoid Arthritis Models

a) *Rabbit model of destructive joint inflammation*

[0197] To study the effects of candidate compounds on inhibiting the inflammatory response of rabbits to an intra-articular injection of the bacterial membrane component lipopolysaccharide
15 (LPS), a rabbit model of destructive joint inflammation is used. This study design mimics the destructive joint inflammation seen in arthritis. Intra-articular injection of LPS causes an acute inflammatory response characterized by the release of cytokines and chemokines, many of which have been identified in rheumatoid arthritic joints. Marked increases in leukocytes occur in synovial fluid and in synovium in response to elevation of these chemotactic mediators.
20 Selective antagonists of chemokine receptors have shown efficacy in this model (see Podolin, *et al.*, *J. Immunol.* 169(11):6435-6444 (2002)).

[0198] A rabbit LPS study is conducted essentially as described in Podolin, et al. *ibid.*, female New Zealand rabbits (approximately 2 kilograms) are treated intra-articularly in one knee with LPS (10 ng) together with either vehicle only (phosphate buffered saline with 1% DMSO) or
25 with addition of candidate compound (dose 1 = 50 μ M or dose 2 = 100 μ M) in a total volume of 1.0 mL. Sixteen hours after the LPS injection, knees are lavaged and cells counts are performed. Beneficial effects of treatment were determined by histopathologic evaluation of synovial

inflammation. Inflammation scores are used for the histopathologic evaluation: 1 - minimal, 2 - mild, 3 - moderate, 4 - moderate-marked.

b) Evaluation of a compound in a rat model of collagen induced arthritis

5 [0199] A 17 day developing type II collagen arthritis study is conducted to evaluate the effects of a candidate compound on arthritis induced clinical ankle swelling. Rat collagen arthritis is an experimental model of polyarthritis that has been widely used for preclinical testing of numerous anti-arthritic agents (see Trentham, et al., *J. Exp. Med.* **146(3)**:857-868 (1977), Bendele, et al., *Toxicologic Pathol.* **27**:134-142 (1999), Bendele, et al., *Arthritis Rheum.* **42**:498-506 (1999)).

10 The hallmarks of this model are reliable onset and progression of robust, easily measurable polyarticular inflammation, marked cartilage destruction in association with pannus formation and mild to moderate bone resorption and periosteal bone proliferation.

[0200] Female Lewis rats (approximately 0.2 kilograms) are anesthetized with isoflurane and injected with Freund's Incomplete Adjuvant containing 2 mg/mL bovine type II collagen at the
15 base of the tail and two sites on the back on days 0 and 6 of this 17 day study. A candidate compound is dosed daily in a sub-cutaneous manner from day 0 till day 17 at a efficacious dose. Caliper measurements of the ankle joint diameter were taken, and reducing joint swelling is taken as a measure of efficacy.

4. Rat model of Sepsis

20 [0201] To study the effect of compounds of interest on inhibiting the generalized inflammatory response that is associated with a sepsis like disease, the Cecal Ligation and Puncture (CLP) rat model of sepsis is used. A Rat CLP study is conducted essentially as described in Fujimura N, et al. (*American Journal Respiratory Critical Care Medicine* 2000; 161: 440-446). Briefly described here, Wistar Albino Rats of both sexes weighing between 200-250 g are fasted for
25 twelve hours prior to experiments. Animals are kept on normal 12 hour light and dark cycles and fed standard rat chow up until 12 hours prior to experiment. Then animals are split into four groups; (i) two sham operation groups and (ii) two CLP groups. Each of these two groups (i.e., (i) and (ii)) is split into vehicle control group and test compound group. Sepsis is induced by the CLP method. Under brief anesthesia a midline laparotomy is made using minimal dissection and

the cecum is ligated just below the ileocaecal valve with 3-0 silk, so the intestinal continuity is maintained. The antimesenteric surface of the cecum is perforated with an 18 gauge needle at two locations 1 cm apart and the cecum is gently squeezed until fecal matter is extruded. The bowel is then returned to the abdomen and the incision is closed. At the end of the operation, all rats are resuscitated with saline, 3 ml/100 g body weight, given subcutaneously. Postoperatively, the rats are deprived of food, but have free access to water for the next 16 hours until they are sacrificed. The sham operated groups are given a laparotomy and the cecum is manipulated but not ligated or perforated. Beneficial effects of treatment are measured by histopathological scoring of tissues and organs as well as measurement of several key indicators of hepatic function, renal function, and lipid peroxidation. To test for hepatic function aspartate transaminase (AST) and alanine transaminase (ALT) are measured. Blood urea nitrogen and creatinine concentrations are studied to assess renal function. Pro-inflammatory cytokines such as TNF-alpha and IL-1beta are also assayed by ELISA for serum levels.

5. Mouse SLE model of experimental lupus nephritis.

[0202] To study the effect of compounds of interest on a Systemic Lupus Erythematosus (SLE), the MRL/*lpr* murine SLE model is used. The MRL/*Mp-Tmfr:sf6^{lpr/lpr}* strain (MRL/*lpr*) is a commonly used mouse model of human SLE. To test compounds efficacy in this model male MRL/*lpr* mice are equally divided between control and C5aR antagonists groups at 13 weeks of age. Then over the next 6 weeks compound or vehicle is administered to the animals via osmotic pumps to maintain coverage and minimize stress effects on the animals. Serum and urine samples are collected bi-weekly during the six weeks of disease onset and progression. In a minority of these mice glomerulosclerosis develops leading to the death of the animal from renal failure. Following mortality as an indicator of renal failure is one of the measured criteria and successful treatment will usually result in a delay in the onset of sudden death among the test groups. In addition, the presence and magnitude of renal disease may also be monitored continuously with blood urea nitrogen (BUN) and albuminuria measurements. Tissues and organs were also harvested at 19 weeks and subjected to histopathology and immunohistochemistry and scored based on tissue damage and cellular infiltration.

6. Rat model of COPD

[0203] Smoke induced airway inflammation in rodent models may be used to assess efficacy of compounds in Chronic Obstructive Pulmonary Disease (COPD). Selective antagonists of chemokines have shown efficacy in this model (*see*, Stevenson, et al., *Am. J. Physiol Lung Cell Mol Physiol.* 288 L514-L522, (2005)). An acute rat model of COPD is conducted as described by Stevenson et al. A compound of interest is administered either systemically via oral or IV dosing; or locally with nebulized compound. Male Sprague-Dawley rats (350-400 g) are placed in Perspex chambers and exposed to cigarette smoke drawn in via a pump (50 mL every 30 seconds with fresh air in between). Rats are exposed for a total period of 32 minutes. Rats are sacrificed up to 7 days after initial exposure. Any beneficial effects of treatment are assessed by a decrease inflammatory cell infiltrate, decreases in chemokine and cytokine levels.

[0204] In a chronic model, mice or rats are exposed to daily tobacco smoke exposures for up to 12 months. Compound is administered systemically via once daily oral dosing, or potentially locally via nebulized compound. In addition to the inflammation observed with the acute model (Stevensen et al.), animals may also exhibit other pathologies similar to that seen in human COPD such as emphysema (as indicated by increased mean linear intercept) as well as altered lung chemistry (see Martorana et al, *Am. J. Respir. Crit Care Med.* 172(7): 848-53.

7. Mouse EAE Model of Multiple Sclerosis

[0205] Experimental autoimmune encephalomyelitis (EAE) is a model of human multiple sclerosis. Variations of the model have been published, and are well known in the field. In a typical protocol, C57BL/6 (Charles River Laboratories) mice are used for the EAE model. Mice are immunized with 200ug myelin oligodendrocyte glycoprotein (MOG) 35–55 (Peptide International) emulsified in Complete Freund's Adjuvant (CFA) containing 4 mg/ml *Mycobacterium tuberculosis* (Sigma-Aldrich) s.c. on day 0. In addition, on day 0 and day 2 animals are given 200 ng of pertussis toxin (Calbiochem) i.v. Clinical scoring is based on a scale of 0–5: 0, no signs of disease; 1, flaccid tail; 2, hind limb weakness; 3, hind limb paralysis; 4, forelimb weakness or paralysis; 5, moribund. Dosing of the compounds of interest to be assessed can be initiated on day 0 (prophylactic) or day 7 (therapeutic, when histological evidence of disease is present but few animals are presenting clinical signs) and dosed once or

more per day at concentrations appropriate for their activity and pharmacokinetic properties, *e.g.* 100 mg/kg s.c. Efficacy of compounds can be assessed by comparisons of severity (maximum mean clinical score in presence of compound compared to vehicle), or by measuring a decrease in the number of macrophages (F4/80 positive) isolated from spinal cords. Spinal cord
5 mononuclear cells can be isolated via discontinuous Percoll-gradient. Cells can be stained using rat anti-mouse F4/80-PE or rat IgG2b-PE (Caltag Laboratories) and quantitated by FACS analysis using 10 ul of Polybeads per sample (Polysciences).

8. Mouse Model of Kidney Transplantation

[0206] Transplantation models can be performed in mice, for instance a model of allogenic
10 kidney transplant from C57BL/6 to BALB/c mice is described in Faikah Gueler et al, JASN Express, Aug 27th, 2008. Briefly, mice are anesthetized and the left donor kidney attached to a cuff of the aorta and the renal vein with a small caval cuff, and the ureters removed en block. After left nephrectomy of the recipient, the vascular cuffs are anastomosed to the recipient abdominal aorta and vena cava, respectively, below the level of the native renal vessels. The
15 ureter is directly anastomosed into the bladder. Cold ischemia time is 60 min, and warm ischemia time is 30 min. The right native kidney can be removed at the time of allograft transplantation or at posttransplantation day 4 for long-term survival studies. General physical condition of the mice is monitored for evidence of rejection. Compound treatment of animals can be started before surgery or immediately after transplantation, eg by sub cut injection once
20 daily. Mice are studied for renal function and survival. Serum creatinine levels are measured by an automated method (Beckman Analyzer, Krefeld, Germany).

9. Mouse Model of Ischemia/Reperfusion

[0207] A mouse model of ischemia/reperfusion injury can be performed as described by
25 Xiufen Zheng et al, *Am. J. Pathol*, Vol 173:4, Oct, 2008. Briefly, CD1 mice aged 6-8 weeks are anesthetized and placed on a heating pad to maintain warmth during surgery. Following abdominal incisions, renal pedicles are bluntly dissected and a microvascular clamp placed on the left renal pedicle for 25-30 minutes. Following ischemia the clamps are removed along with the right kidney, incisions sutured, and the animals allowed to recover. Blood is collected for serum creatinine and BUN analysis as an indicator of kidney health. Alternatively animal

survival is monitored over time. Compound can be administered to animals before and/or after the surgery and the effects on serum creatinine, BUN or animal survival used as indicators of compound efficacy.


10. Mouse Model of Tumor Growth

- 5 [0208] C57BL/6 mice 6–16 weeks of age are injected subcutaneously with 1×10^5 TC-1 cells (ATCC, VA) in the right or left rear flank. Beginning about 2 weeks after cell injection, tumors are measured with calipers every 2–4 d until the tumor size required the mice are killed. At the time of sacrifice animals are subjected to a full necropsy and spleens and tumors removed. Excised tumors are measured and weighed. Compounds may be administered before and/or after
10 tumor injections, and a delay or inhibition of tumor growth used to assess compound efficacy.

Example 13

- [0209] The compounds in **Table 1**, below, were prepared using the methods described above. Characterization data is provided for each compound listed. Activity is provided as follows for
15 the chemotaxis assay using U937 cells as described herein (Example 12): +, $500 \text{ nM} < \text{IC}_{50}$; ++, $50 \text{ nM} < \text{IC}_{50} \leq 500 \text{ nM}$; +++, $5 \text{ nM} < \text{IC}_{50} \leq 50 \text{ nM}$; and +++++, $\text{IC}_{50} \leq 5 \text{ nM}$.








Table 1: Structure, Characterization Data and Biological Activity Data of Specific Embodiments

Compound Number	Structure	MS: ES (m/z) [M+H] ⁺	Mig IC ₅₀ (nM)
1.001		550.2	+++++








1.002		667.2	++
1.003		637.2	++++
1.004		609.2	+++
1.005		562.4	+++
1.006		651.2	+++
1.007		578.4	++++
1.008		564.6	++++

1.009		482.6	+++
1.010		538.4	+++
1.011		680.6	++++
1.012		630.5	++++
1.013		585.5	++++
1.014		612.4	++++
1.015		632.4	++++

1.016		666.6	++++
1.017		612.4	++++
1.018		585.5	++++
1.019		524.4	+++
1.020		510.4	+++
1.021		632.4	++++
1.022		666.6	++++








1.023		612.5	++++
1.024		612.5	++++
1.025		540.6	++++
1.026		545.4	+++
1.027		612.4	++++
1.028		602.4	++++
1.029		566.6	+++








1.030		496.5	+++
1.031		646.6	++++
1.032		524.6	++++
1.033		652.6	++++
1.034		598.6	++++
1.035		646.6	++++
1.036		598.6	++++








1.037		614.6	++++
1.038		618.4	++++
1.039		602.4	++++
1.040		552.5	++++
1.041		547.5	+
1.042		664.6	++++
1.043		536.5	++++








1.044		602.5	++++
1.045		614.6	++++
1.046		552.6	++++
1.047		626.5	++++
1.048		609.4	++++
1.049		598.6	++++
1.050		630.6	++++

1.051		516.5	++++
1.052		646.6	++++
1.053		614.4	++++
1.054		572.5	++++
1.055		652.6	++++
1.056		614.4	++++
1.057		618.4	++++








1.058		614.4	++++
1.059		680.6	++++
1.060		624.6	+++
1.061		590.5	++++
1.062		670.6	++++
1.063		544.6	++++
1.064		598.6	++++

1.065		584.6	++++
1.066		602.4	++++
1.067		584.5	++++
1.068		648.6	++++
1.069		618.5	++++
1.070		584.5	++++
1.071		560.5	+++

1.079		546.5	+++
1.080		574.5	++++
1.081		498.5	+++
1.082		480.5	++
1.083		498.5	+++
1.084		544.6	++++
1.085		546.5	+++








1.086		470.5	+
1.087		518.3	++
1.088		470.5	+
1.089		533.5	++++
1.090		540.5	++++
1.091		577.5	++++
1.092		516.6	++++








1.093		548.5	++++
1.094		560.5	++++
1.095		508.5	++++
1.096		516.6	++++
1.097		539.3	++++
1.098		564.4	++++
1.099		576.2	++++

1.100		516.6	++++
1.101		552.3	+
1.102		534.5	++++
1.103		508.1	++++
1.104		567.5	++
1.105		567.5	+++
1.106		526.5	++++








1.107		526.5	++++
1.108		506.3	+
1.109		492.3	++
1.110		510.3	+
1.111		572.3	++++
1.112		501.0	++++
1.113		551.5	++++








1.114		554.3	++++
1.115		523.5	++++
1.116		557.3	+
1.117		556.6	++++
1.118		538.5	++++
1.119		542.3	++++
1.120		500.2	+

1.121		515.2	+
1.122		560.5	++++
1.123		555.3	++++
1.124		549.5	++++
1.125		558.5	++
1.126		542.4	++
1.127		509.4	++++








1.128		539.4	++++
1.129		589.2	++++
1.130		605.3	++++
1.131		590.2	++++
1.132		527.1	++++
1.133		517.3	++
1.134		538.5	+++

1.135		559.2	+
1.136		586.2	++++
1.137		602.6	++++
1.138		572.2	++++
1.139		576.2	++++
1.140		573.3	+
1.141		568.1	++++

1.142		573.2	+++
1.143		613.0	++++
1.144		612.2	++++
1.145		574.4	++++
1.146		516.4	++++
1.147		583.1	++++
1.148		574.2	++++








1.149		574.2	++++
1.150		562.2	++++
1.151		530.4	++++
1.152		548.2	++++
1.153		518.2	+++
1.154		544.1	++++
1.155		510.1	+++








1.156		574.2	++++
1.157		574.2	++++
1.158		548.2	++++
1.159		552.2	++++
1.160		534.2	++++
1.161		548.4	++++
1.162		544.2	++++








1.163		612.2	++++
1.164		602.4	++++
1.165		535.2	++++
1.166		576.2	++++
1.167		599.0	++++
1.168		581.2	++++
1.169		585.1	++++








1.170		567.1	++++
1.171		588.2	+++
1.172		591.2	++++
1.173		585.1	++++
1.174		561.1	++++
1.175		568.6	++++
1.176		547.0	++++








1.177		581.6	++++
1.178		551.2	++++
1.179		563.0	+++
1.180		543.1	++++
1.181		548.3	++++
1.182		567.5	++++
1.183		551.0	+++








1.184		559.4	++++
1.185		589.5	++++
1.186		562.2	++++
1.187		583.0	+++
1.188		605.1	++++
1.189		587.1	++++
1.190		581.5	++++








1.191		575.2	++++
1.192		562.2	++++
1.193		548.2	++
1.194		600.1	++++
1.195		562.2	++++
1.196		614.2	++++
1.197		594.4	++++








1.198		578.3	++++
1.199		560.3	++++
1.200		544.2	++++
1.201		571.1	++++
1.202		593.3	++++
1.203		623.2	++++
1.204		482.2	+++








1.205		605.2	++++
1.206		563.2	++++
1.207		574.3	++++
1.208		598.5	++++
1.209		523.3	++
1.210		601.5	++++
1.211		615.2	++++

1.212		496.3	++++
1.213		563.6	++++
1.214		526.3	++++
1.215		492.3	+++
1.216		504.3	+++
1.217		635.2	++++
1.218		575.3	++++








1.219		478.3	+++
1.220		573.3	++++
1.221		478.3	++
1.222		635.2	++++
1.223		518.3	++++
1.224		547.2	++++
1.225		596.2	++++

1.226		608.2	+
1.227		553.1	++++
1.228		567.2	++++
1.229		646.2	+++
1.230		508.3	+++
1.231		494.3	+++
1.232		548.3	++++








1.233		532.3	+
1.234		535.3	+++
1.235		464.2	+++
1.236		571.2	++++
1.237		578.2	+++
1.238		534.2	+++
1.239		522.3	++++








1.240		597.2	++++
1.241		616.2	++++
1.242		619.2	++++
1.243		490.3	++++
1.244		566.2	++++
1.245		555.3	+++
1.246		556.3	+++

1.247		508.3	++++
1.248		522.3	++
1.249		551.2	++++
1.250		565.1	++++
1.251		551.2	+++
1.252		583.5	++++
1.253		478.3	++++

1.254		534.3	++++
1.255		508.3	++++
1.256		534.3	++++
1.257		508.3	++++
1.258		565.2	+++
1.259		494.3	+++
1.260		518.3	+








1.261		606.5	+
1.262		548.2	++++
1.263		619.2	++
1.264		480.3	++
1.265		466.2	++
1.266		611.2	+
1.267		613.3	+++








1.268		597.3	+++
1.269		617.2	++++
1.270		601.2	++++
1.271		565.2	+++
1.272		520.3	++++
1.273		494.3	+++
1.274		508.3	++++








1.275		617.3	++++
1.276		617.3	++++
1.277		664.2	++++
1.278		582.2	+++
1.279		574.3	+++
1.280		602.3	+++
1.281		590.3	++++

1.282		460.3	+++
1.283		481.2	+
1.284		572.3	+++
1.285		514.3	+++
1.286		576.3	+++
1.287		539.2	+++
1.288		601.3	++++

1.289		611.3	+
1.290		508.3	+++
1.291		548.2	+++
1.292		582.2	+++
1.293		548.2	+++
1.294		558.3	+++
1.295		562.3	+++

1.296		579.2	++++
1.297		582.2	+++
1.298		628.2	++
1.299		630.2	++++
1.300		592.3	++++
1.301		553.2	+++
1.302		574.2	+++








1.303		592.3	+++
1.304		574.3	+++
1.305		592.3	+++
1.306		592.3	++++
1.307		564.3	+++
1.308		542.3	++++
1.309		562.3	++++








1.310		546.3	+++
1.311		581.2	+++
1.312		558.3	++++
1.313		544.3	+++
1.314		592.3	+++
1.315		612.4	++++
1.316		546.2	++++








1.317		598.2	++++
1.318		582.2	++++
1.319		592.3	++++
1.320		562.4	++++
1.321		578.2	++++
1.322		583.2	++++
1.323		562.3	++++








1.324		578.3	++++
1.325		612.2	++++
1.326		562.3	++++
1.327		612.4	++++
1.328		578.2	++++
1.329		596.2	++++
1.330		592.3	++++








1.331		592.3	++++
1.332		680.2	++++
1.333		646.2	++++
1.334		664.2	++++
1.335		646.3	++++
1.336		488.3	+++
1.337		644.2	+++

1.338		578.3	+++
1.339		633.2	++++
1.340		579.2	+++
1.341		566.2	+++
1.342		632.2	++++
1.343		632.2	++++
1.344		598.3	++++








1.345		578.3	++++
1.346		584.2	+++
1.347		553.3	++++
1.348		553.3	+++
1.349		501.2	++
1.350		562.2	+++
1.351		596.3	++++








1.352		566.2	+++
1.353		599.2	+++
1.354		558.5	+++
1.355		553.3	+++
1.356		546.3	+++
1.357		646.3	++++
1.358		596.3	++++








1.359		558.3	++++
1.360		542.3	++++
1.361		578.3	++++
1.362		612.2	++++
1.363		572.4	++
1.364		569.5	+
1.365		552.3	++++








1.366		570.3	+++
1.367		578.2	+++
1.368		582.2	+++
1.369		582.2	+++
1.370		553.3	+++
1.371		524.3	+++
1.372		542.3	+++

1.373		544.2	+++
1.374		583.2	+++
1.375		598.2	+++
1.376		538.3	+++
1.377		578.2	+++
1.378		582.2	+++
1.379		598.2	+++








1.380		522.3	+++
1.381		504.3	+++
1.382		510.3	+++
1.383		569.3	++
1.384		592.3	+++
1.385		476.3	++
1.386		583.3	+++








1.387		564.5	+++
1.388		536.5	+++
1.389		492.3	+
1.390		552.3	+++
1.391		530.2	+++
1.392		566.3	+++
1.393		504.3	++








1.394		551.3	++++
1.395		553.3	+++
1.396		552.3	+++
1.397		502.3	++
1.398		552.3	++++
1.399		476.3	++
1.400		564.5	+








1.401		550.5	++++
1.402		536.5	+
1.403		522.5	++
1.404		502.3	+++
1.405		490.3	+++
1.406		502.3	++
1.407		564.6	+++








1.408		469.2	++
1.409		538.3	+++
1.410		488.3	++
1.411		505.3	+
1.412		564.2	++++
1.413		598.2	+++
1.414		518.3	++

1.415		504.3	++
1.416		476.3	+
1.417		462.2	++
1.418		578.3	+++
1.419		556.3	+++
1.420		447.2	+
1.421		570.3	++++








1.422		586.6	+++
1.423		528.3	+++
1.424		534.3	+
1.425		530.3	+
1.426		502.2	++
1.427		570.3	++++
1.428		490.3	++








1.429		552.3	++
1.430		538.3	+
1.431		524.2	++
1.432		580.3	++
1.433		580.3	++
1.434		566.3	++
1.435		518.3	++








1.436		504.3	++
1.437		519.3	+
1.438		516.3	++
1.439		520.3	+++
1.440		578.3	+++
1.441		580.3	++++
1.442		508.3	+++








1.443		565.3	++
1.444		552.3	++++
1.445		551.3	+++
1.446		508.3	+
1.447		497.2	++
1.448		570.5	+++
1.449		552.3	+








1.450		524.3	++
1.451		528.2	++
1.452		466.3	+++
1.453		537.3	+++
1.454		552.3	++++
1.455		509.3	+++
1.456		510.2	+++

1.457		566.3	++++
1.458		523.3	+++
1.459		467.3	+++
1.460		524.3	++++
1.461		484.2	++
1.462		524.3	+++
1.463		494.3	++++

1.464		441.2	++
1.465		481.2	+++
1.466		494.3	++++
1.467		452.3	++
1.468		451.3	++
1.469		481.3	++
1.470		465.3	+++

1.471		451.3	+++
1.472		480.3	++
1.473		452.2	++
1.474		538.3	++++
1.475		510.2	+++
1.476		481.2	+++
1.477		479.3	++

1.478		480.2	++
1.479		467.2	++
1.480		495.5	+++
1.481		437.3	+++
1.482		496.4	+++
1.483		495.4	+
1.484		468.3	++

1.485		495.5	++
1.486		453.4	++
1.487		453.4	+
1.488		524.5	+
1.489		467.4	+
1.490		493.5	+
1.491		425.4	++

[0210] While particular embodiments of this invention are described herein, upon reading
5 the description, variations of the disclosed embodiments may become apparent to individuals
working in the art, and it is expected that those skilled artisans may employ such variations
as appropriate. Accordingly, it is intended that the invention be practiced otherwise than as
specifically described herein, and that the invention includes all modifications and
equivalents of the subject matter recited in the claims appended hereto as permitted by
10 applicable law. Moreover, any combination of the above-described elements in all possible
variations thereof is encompassed by the invention unless otherwise indicated herein or
otherwise clearly contradicted by context.

[0211] All publications, patent applications, accession numbers, and other references cited in
this specification are herein incorporated by reference as if each individual publication or patent
15 application were specifically and individually indicated to be incorporated by reference.


PATENT

Attorney Docket No. 50779-581P01US-011800US

Client Ref. No. T11800US

WHAT IS CLAIMED IS:

1 1. A compound of Formula (I)



2
3 or a pharmaceutically acceptable salt thereof, wherein,

4 ring vertex a is N or C(R^{2c}), ring vertex b is N or C(R^{2d}), and ring vertex e is N or C(R^{2e}),

5 wherein no more than one of a, b and e is N;

6 X¹ is selected from the group consisting of a bond, C₁₋₈ alkylene, C(O), C(O)-C₁₋₄ alkylene,
7 and S(O)₂;

8 R¹ is selected from the group consisting of

9 a) 5- to 10-membered heteroaryl having from 1 to 4 heteroatoms as ring vertices selected
10 from N, O and S;

11 b) C₆₋₁₀ aryl;

12 c) C₃₋₈ cycloalkyl;

13 d) 4- to 8-membered heterocycloalkyl having from 1 to 2 heteroatoms as ring vertices
14 selected from N, O and S; and

15 e) C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ haloalkyl, -C(O)NR^{1a}R^{1b}, and -CO₂R^{1a}; wherein R^{1a} and
16 R^{1b} are each independently selected from the group consisting of hydrogen, C₁₋₈ alkyl,
17 C₆₋₁₀ aryl, and -C₁₋₆ alkylene-C₆₋₁₀ aryl;

18 wherein the group -X¹-R¹ is optionally substituted with 1 to 5 R^x substituents;

19 R^{2a} and R^{2e} are each independently selected from the group consisting of hydrogen, C₁₋₆


20 alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, -O-C₁₋₆ haloalkyl, -S-C₁₋₆ alkyl, -C₁₋₆ alkyl-O-C₁₋₆

21 alkyl, -C₁₋₆ alkyl-S-C₁₋₆ alkyl, CN, and halogen, and at least one of R^{2a} and R^{2e} is other

22 than hydrogen;


23 R^{2b} , R^{2c} , and R^{2d} are each independently selected from the group consisting of hydrogen, C_{1-6}
 24 alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, $-O-C_{1-6}$ haloalkyl, $-S-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $O-C_{1-6}$
 25 alkyl, $-C_{1-6}$ alkyl- $S-C_{1-6}$ alkyl, cyano, and halogen;
 26 each R^3 is independently selected from the group consisting of hydroxyl, C_{1-4} alkyl, C_{1-4}
 27 haloalkyl and C_{1-4} hydroxyalkyl, and optionally two R^3 groups on the same carbon
 28 atom are combined to form oxo (=O), and optionally two R^3 groups and the carbon
 29 atoms they are attached to form a 3-6 membered ring with 0-2 heteroatoms as ring
 30 members selected from O, N, and S;
 31 R^4 is independently selected from the group consisting of $-X^2-OR^{4a}$, $-X^2-NR^{4a}R^{4b}$,
 32 $-X^2-CONR^{4a}R^{4b}$, $-X^2-NR^{4a}-C(O)R^{4a}$, $-X^2-NR^{4a}-C(O)NR^{4a}R^{4b}$, $-X^2-NR^{4a}-C(O)OR^{4a}$,
 33 $-X^2-NR^{4a}-C(O)-C_{1-3}$ alkylene- OR^{4a} and $-X^2-NR^{4a}-C(O)-C_{1-3}$ alkylene- $NR^{4a}R^{4b}$;
 34 wherein each X^2 is independently a bond, C(O), C_{1-4} alkylene, C(O)- C_{1-4} alkylene, and
 35 C_{1-4} alkylene-C(O), and each R^{4a} and R^{4b} is independently selected from the group
 36 consisting of hydrogen, C_{1-4} alkyl, and C_{1-4} haloalkyl;
 37 each R^5 is independently selected from the group consisting of C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8}
 38 haloalkyl, C_{1-8} haloalkoxy, C_{1-8} hydroxyalkyl, halogen, OH, CN, C(O) R^{5a} and CO_2R^{5a} ,
 39 wherein each R^{5a} is independently selected from the group consisting of hydrogen, C_{1-4}
 40 alkyl, and C_{1-4} haloalkyl;
 41 each R^x is independently selected from the group consisting of halogen, CN, C_{1-4} alkyl, C_{1-4}
 42 alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{1-4} hydroxy, C_{2-4} alkenyl, C_{3-6} cycloalkyl,
 43 CO_2-C_{1-4} alkyl, and $CONH_2$;
 44 the subscript m is 0, 1, 2, 3 or 4; and
 45 the subscript n is 0, 1, 2 or 3.

1 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein R^4 is selected from the group consisting of




3

1 3. The compound of any one of claims 1 or 2, or a pharmaceutically
 2 acceptable salt thereof, wherein R^4 is selected from the group consisting of



3

1 4. The compound of any one of claims 1 to 3, or a pharmaceutically
 2 acceptable salt thereof, wherein R^4 is selected from the group consisting of



3

1 5. The compound of any one of claims 1 to 4, or a pharmaceutically
 2 acceptable salt thereof, wherein X^1 is a bond.

1 6. The compound of any one of claims 1 to 4, or a pharmaceutically
 2 acceptable salt thereof, wherein X^1 is C(O).

1 7. The compound of any one of claims 1 to 4, or a pharmaceutically
 2 acceptable salt thereof, wherein X^1 is C_{1-8} alkylene.

1 8. The compound of any one of claims 1 to 4, or a pharmaceutically
 2 acceptable salt thereof, wherein X^1 is C(O)- C_{1-4} alkylene or S(O)₂.

1 **9.** The compound of any one of claims **1** to **8**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is a 5- to 10-membered heteroaryl having from 1 to 4
3 heteroatoms as ring vertices selected from N, O and S; and wherein the group $-X^1-R^1$ is
4 optionally substituted with 1 to 4 R^x substituents.

1 **10.** The compound of claim **9**, wherein R^1 is selected from the group
2 consisting of pyrazolyl, pyridyl, pyrimidinyl, imidazolyl, thiazolyl, thiadiazolyl and pyrazinyl;
3 and wherein the group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x substituents.

1 **11.** The compound of any one of claims **1** to **8**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is C_{6-10} aryl; and wherein the group $-X^1-R^1$ is optionally
3 substituted with 1 to 4 R^x substituents.

1 **12.** The compound of claim **11**, wherein R^1 is phenyl; and wherein the group $-$
2 X^1-R^1 is optionally substituted with 1 to 4 R^x substituents.

1 **13.** The compound of any one of claims **1** to **8**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is C_{3-8} cycloalkyl; and wherein the group $-X^1-R^1$ is optionally
3 substituted with 1 to 4 R^x substituents.

1 **14.** The compound of claim **13**, wherein R^1 is selected from the group
2 consisting of cyclobutyl, cyclopentyl and cyclohexyl; and wherein the group $-X^1-R^1$ is optionally
3 substituted with 1 to 4 R^x substituents.

1 **15.** The compound of any one of claims **1** to **8**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is a 4- to 8-membered heterocycloalkyl having from 1 to 2
3 heteroatoms as ring vertices selected from N, O and S; and wherein the group $-X^1-R^1$ is
4 optionally substituted with 1 to 4 R^x substituents.

1 **16.** The compound of claim **15**, wherein R^1 is selected from the group
2 consisting of oxetanyl, tetrahydrofuranyl, tetrahydropyranyl and morpholinyl; and wherein the
3 group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x substituents.

1 **17.** The compound of any one of claims **1** to **8**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is selected from the group consisting of C_{1-8} alkyl, C_{1-8}
3 alkoxy, C_{1-8} haloalkyl, $-C(O)NR^{1a}R^{1b}$, and $-CO_2R^{1a}$, wherein R^{1a} and R^{1b} are each independently
4 selected from the group consisting of hydrogen, C_{1-8} alkyl, C_{6-10} aryl, and $-C_{1-6}$ alkylene- C_{6-10}
5 aryl; and wherein the group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x substituents.

1 **18.** The compound of any one of claims **1** to **8**, or a pharmaceutically
2 acceptable salt thereof, wherein R^1 is selected from the group consisting of phenyl, pyridyl,
3 pyrimidinyl, and pyrazinyl; and wherein the group $-X^1-R^1$ is optionally substituted with 1 to 4 R^x
4 substituents.

1 **19.** The compound of any one of claims **1** to **18**, or a pharmaceutically
2 acceptable salt thereof, wherein ring vertices a and b are CH; R^{2b} is H; ring vertex e is $C(R^{2e})$,
3 and R^{2a} and R^{2c} are independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy,
4 C_{1-6} haloalkyl, $-O-C_{1-6}$ haloalkyl, $-S-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $O-C_{1-6}$ alkyl, $-C_{1-6}$ alkyl- $S-C_{1-6}$ alkyl,
5 CN, and halogen.


1 **20.** The compound of any one of claims **1** to **18**, or a pharmaceutically
2 acceptable salt thereof, wherein ring vertices a and b are CH; R^{2b} is H; ring vertex e is $C(R^{2e})$,
3 and R^{2a} and R^{2c} are independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} alkoxy
4 and halogen.

1 **21.** The compound of any one of claims **1** to **20**, or a pharmaceutically
2 acceptable salt thereof, wherein n is 0, 1 or 2 and each R^5 , when present, is selected from the
3 group consisting of F, Cl, CN, C_{1-4} alkyl and C_{1-4} alkoxy.

1 **22.** The compound of any one of claims **1** to **20**, or a pharmaceutically
2 acceptable salt thereof, wherein n is 0, 1 or 2 and each R^5 , when present, is selected from the
3 group consisting of F, Cl, CN, CH_3 and OCH_3 .

1 **23.** The compound of any one of claims **1** to **20**, or a pharmaceutically
2 acceptable salt thereof, wherein m is 0, 1 or 2 and each R^3 , when present, is C_{1-4} alkyl.

1 **24.** The compound of claim 1, or a pharmaceutically acceptable salt
 2 thereof, wherein R¹ is selected from the group consisting of phenyl or pyridyl, wherein the
 3 group -X¹-R¹ is optionally substituted with 1 to 4 R^x substituents; ring vertices a and b are
 4 CH; R^{2b} is H; ring vertex e is C(R^{2e}), and R^{2a} and R^{2e} are independently selected from the group
 5 consisting of C₁₋₆ alkyl, C₁₋₆ alkoxy and halogen; m is 0, 1 or 2 and each R³, when present, is
 6 CH₃; R⁴ is selected from the group consisting of



and





7

;


8 n is 0, 1 or 2 and each R⁵, when present, is selected from the group consisting of F, Cl, CN, CH₃
 9 and OCH₃.

1 **25.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein R¹ is selected from the group consisting of





27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of:




3


1

2

3

28. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of:







3

1

30. The compound of any one of claims **1** to **29**, or a pharmaceutically

2

acceptable salt thereof, wherein  is selected from the group consisting of



3

1

31. The compound of any one of claims **1** to **30**, or a pharmaceutically

2

acceptable salt thereof, wherein n is 0.

1

32. The compound of any one of claims **1** to **30**, or a pharmaceutically


2

acceptable salt thereof, wherein n is 2 and the two R^3 groups are on the same carbon atom and

3

are combined to form oxo ($=O$).

- 1 **33.** The compound of claim 1, or a pharmaceutically acceptable salt thereof,
 2 wherein said compound is selected from the group consisting of



1 **34.** A pharmaceutical composition comprising a compound of any one of
2 claims **1** to **33** or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable
3 carrier.

1 **35.** The pharmaceutical composition of claim **34**, formulated for oral,
2 intravenous, transdermal or subcutaneous administration.

1 **36.** The pharmaceutical composition of claim **34** or **35**, further comprising one
2 or more additional therapeutic agents.

1 **37.** The pharmaceutical composition of claim **36**, wherein the one or more
2 additional therapeutic agent is selected from the group consisting of corticosteroids, steroids,
3 immunosuppressants, Immunoglobulin G agonists, Dipeptidyl peptidase IV inhibitors,
4 Lymphocyte function antigen-3 receptor antagonists, Interleukin-2 ligands, Interleukin-1 beta
5 ligand inhibitors, IL-2 receptor alpha subunit inhibitors, HGF gene stimulators, IL-6 antagonists,
6 IL-5 antagonists, Alpha 1 antitrypsin stimulators, Cannabinoid receptor antagonists, Histone
7 deacetylase inhibitors, AKT protein kinase inhibitors, CD20 inhibitors, Abl tyrosine kinase
8 inhibitors, JAK tyrosine kinase inhibitors, TNF alpha ligand inhibitors, Hemoglobin modulators,
9 TNF antagonists, proteasome inhibitors, CD3 modulators, Hsp 70 family inhibitors,
10 Immunoglobulin agonists, CD30 antagonists, tubulin antagonists, Sphingosine-1-phosphate
11 receptor-1 agonists, connective tissue growth factor ligand inhibitors, caspase inhibitors,
12 adrenocorticotrophic hormone ligands, Btk tyrosine kinase inhibitors, Complement C1s
13 subcomponent inhibitors, Erythropoietin receptor agonists, B-lymphocyte stimulator ligand
14 inhibitors, Cyclin-dependent kinase-2 inhibitors, P-selectin glycoprotein ligand-1 stimulators,
15 mTOR inhibitors, Elongation factor 2 inhibitors, Cell adhesion molecule inhibitors, Factor XIII
16 agonists, Calcineurin inhibitors, Immunoglobulin G1 agonists, Inosine monophosphate
17 dehydrogenase inhibitors, Complement C1s subcomponent inhibitors, Thymidine kinase
18 modulators, Cytotoxic T-lymphocyte protein-4 modulators, Angiotensin II receptor antagonists,
19 Angiotensin II receptor modulators, TNF superfamily receptor 12A antagonists, CD52
20 antagonists, Adenosine deaminase inhibitors, T-cell differentiation antigen CD6 inhibitors, FGF-
21 7 ligands, dihydroorotate dehydrogenase inhibitors, Syk tyrosine kinase inhibitors, Interferon
22 type I receptor antagonists, Interferon alpha ligand inhibitors, Macrophage migration inhibitory

23 factor inhibitors, Integrin alpha-V/beta-6 antagonists, Cysteine protease stimulators, p38 MAP
 24 kinase inhibitors, TP53 gene inhibitors, Shiga like toxin I inhibitors, Fucosyltransferase 6
 25 stimulators, Interleukin 22 ligands, IRS1 gene inhibitors, Protein kinase C stimulators, Protein
 26 kinase C alpha inhibitors, CD74 antagonists, Immunoglobulin gamma Fc receptor IIB
 27 antagonists, T-cell antigen CD7 inhibitors, CD95 antagonists, N acetylmannosamine kinase
 28 stimulators, Cardiotrophin-1 ligands, Leukocyte elastase inhibitors, CD40 ligand receptor
 29 antagonists, CD40 ligand modulators, IL-17 antagonists, TLR-2 antagonists, Mannan-binding
 30 lectin serine protease-2 (MASP-2) inhibitors, Factor B inhibitors, Factor D inhibitors, C3aR
 31 modulators, C5aR2 modulators, T cell receptor antagonists, PD-1 inhibitors, PD-L1 inhibitors,
 32 TIGIT inhibitors, TIM-3 inhibitors, LAG-3 inhibitors, VISTA inhibitors, STING agonists, IDO
 33 inhibitors, adenosine receptor modulators, CD39 inhibitors, CD73 inhibitors, antagonists of the
 34 chemokine receptors, especially CXCR1, CXCR2, CXCR3, CXCR4, CXCR7, CCR1, CCR2,
 35 CCR3, CCR4, CCR5, CCR7, CCR7, CCR9, CX3CR1 and CXCR6, and combinations thereof.

1 **38.** The pharmaceutical composition of any one of claims **36** or **37**,
 2 wherein the one or more additional therapeutic agent is selected from the group consisting of
 3 obinutuzumab, rituximab, ocrelizumab, cyclophosphamide, prednisone, hydrocortisone,
 4 hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone,
 5 methylprednisolone, triamcinolone acetonide, triamcinolone alcohol, mometasone,
 6 amcinonide, budesonide, desonide, flucinonide, flucinolone acetonide, halcinonide,
 7 betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium
 8 phosphate, fluocortolone, hydrocortisone-17-valerate, halometasone, alclometasone
 9 dipropionate, beclomethasone, betamethasone valerate, betamethasone dipropionate,
 10 prednicarbate, clobetasone-17-butyrate, clobetasol-17-propionate, fluocortolone caproate,
 11 fluocortolone pivalate, fluprednidene acetate, hydrocortisone-17-butyrate, hydrocortisone-
 12 17-aceponate, hydrocortisone-17-buteprate, ciclesonide and prednicarbate, GB-0998,
 13 immuglo, begelomab, alefacept, aldesleukin, gevokizumab, daclizumab, basiliximab,
 14 inolimomab, beperminogene perplasmid, sirukumab, tocilizumab, clazakizumab,
 15 mepolizumab, fingolimod, panobinostat, triciribine, nilotinib, imatinib, tofacitinib,
 16 momelotinib, peficitinib, itacitinib, infliximab, PEG-bHb-CO, etanercept, ixazomib,
 17 bortezomib, muromonab, otelixizumab, gusperimus, brentuximab vedotin, Ponesimod, KRP-

18 203, FG-3019, emricasan, corticotropin, ibrutinib, cinryze, conestat, methoxy polyethylene
 19 glycol-epoetin beta, belimumab, blisibimod, atacicept, seliciclib, neihulizumab, everolimus,
 20 sirolimus, denileukin diftitox, LMB-2, natalizumab, catridecacog, ciclosporin, tacrolimus,
 21 voclosporin, voclosporin, canakinumab, mycophenolate, mizoribine, CE-1145, TK-DLI,
 22 abatacept, belatacept, olmesartan medoxomil, sparsentan, TXA-127, BIIB-023,
 23 alemtuzumab, pentostatin, itolizumab, palifermin, leflunomide, PRO-140, cenicriviroc,
 24 fostamatinib, anifrolumab, sifalimumab, BAX-069, BG-00011, losmapimod, QPI-1002,
 25 ShigamAbs, TZ-101, F-652, reparixin, ladarixin, PTX-9908, aganirsen, APH-703,
 26 sotrastaurin, sotrastaurin, milatuzumab, SM-101, T-Guard, APG-101, DEX-M74,
 27 cardiotrophin-1, tiprelestat, ASKP-1240, BMS-986004, HPH-116, KD-025, OPN-305, TOL-
 28 101, defibrotide, pomalidomide, Thymoglobulin, laquinimod, remestemcel-L, Equine
 29 antithymocyte immunoglobulin, Stempeucel, LIV-Gamma, Octagam 10%, t2c-001, 99mTc-
 30 sestamibi, Clairryg, ProSORBA, pomalidomide, laquinimod, teplizumab, FCRx, solnatide,
 31 foralumab, ATIR-101, BPX-501, ACP-01, ALLO-ASC-DFU, irbesartan + propagermanium,
 32 ApoCell, cannabidiol, RGI-2001, saratin, anti-CD3 bivalent antibody-diphtheria toxin
 33 conjugate, NOX-100, LT-1951, OMS721, ALN-CC5, ACH-4471, AMY-101, Acthar gel,
 34 and CD4+CD25+ regulatory T-cells, MEDI7814, P32, P59, pembrolizumab, nivolumab,
 35 atezolizumab, avelumab, durvalumab, CCX354, CCX721, CCX9588, CCX140, CCX872,
 36 CCX598, CCX6239, CCX587, CCX624, CCX282, CCX025, CCX507, CCX430, CCX765,
 37 CCX758, CCX771, CCX662, CCX650, and combinations thereof..

1 **39.** A method of treating a human suffering from or susceptible to a disease or
 2 disorder involving pathologic activation of C5a receptors, comprising administering to the
 3 mammal a therapeutically effective amount of a compound of any one of claims 1 to 16 or a
 4 pharmaceutical composition of any one of claims **34** to **38**.

1 **40.** The method of claim **39**, wherein the disease or disorder is an
 2 inflammatory disease or disorder, an autoimmune disease, or an oncologic disease or disorder.

1 **41.** The method of claim **39**, wherein the disease or disorder is a
 2 cardiovascular or cerebrovascular disorder.

1 **42.** The method of claim **39**, wherein the disease or disorder is selected from
2 the group consisting of neutropenia, neutrophilia, Wegener's granulomatosis, microscopic
3 polyangiitis, C3-glomerulopathy, C3-glomerulonephritis, dense deposit disease,
4 membranoproliferative glomerulonephritis, Kawasaki disease, sepsis, septic shock, Hemolytic
5 uremic syndrome, atypical hemolytic uremic syndrome (aHUS), Alzheimer's disease, multiple
6 sclerosis, stroke, inflammatory bowel disease, chronic obstructive pulmonary disorder,
7 inflammation associated with burns, lung injury, osteoarthritis, atopic dermatitis, chronic
8 urticaria, ischemia-reperfusion injury, acute respiratory distress syndrome, systemic
9 inflammatory response syndrome, multiple organ dysfunction syndrome, Uveitis, tissue graft
10 rejection, hyperacute rejection of transplanted organs, myocardial infarction, coronary
11 thrombosis, vascular occlusion, post-surgical vascular reocclusion, atherosclerosis, polypoidal
12 choroidal vasculopathy, traumatic central nervous system injury, ischemic heart disease,
13 rheumatoid arthritis, systemic lupus erythematosus, Guillain- Barre syndrome, pancreatitis, lupus
14 nephritis, lupus glomerulonephritis, psoriasis, Crohn's disease, vasculitis, ANCA vasculitis,
15 irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus,
16 pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and thrombocytopenic
17 states, Goodpasture's syndrome, immuno vasculitis, Graft versus host disease, Paroxysmal
18 nocturnal hemoglobinuria, Sjogrens syndrome, insulin-dependent diabetes, mellitus, lupus
19 nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, IGA nephropathy,
20 Membranoproliferative glomerulonephritis, Antiphospholipid syndrome, Age related macular
21 degeneration; Dry age related macular degeneration, Wet age related macular degeneration,
22 Motor neurone disease, contact sensitivity responses, hidradenitis suppurativa, and inflammation
23 resulting from contact of blood with artificial surfaces.

1 **43.** The method of claim **39**, wherein the disease or disorder is selected from
2 the group consisting of neutropenia, neutrophilia, Wegener's granulomatosis, microscopic
3 polyangiitis, C3-glomerulopathy, C3-glomerulonephritis, dense deposit disease,
4 membranoproliferative glomerulonephritis, Kawasaki disease, Hemolytic uremic syndrome,
5 atypical hemolytic uremic syndrome (aHUS), tissue graft rejection, hyperacute rejection of
6 transplanted organs, rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, lupus
7 glomerulonephritis, vasculitis, ANCA vasculitis, autoimmune hemolytic and thrombocytopenic

8 states, immuno vasculitis, Graft versus host disease, lupus nephropathy, Heyman nephritis,
9 membranous nephritis, glomerulonephritis, IGA nephropathy, hidradenitis suppurativa, and
10 Membranoproliferative glomerulonephritis.

1 **44.** The method of claim **39**, wherein the disease or disorder is selected from
2 the group consisting of melanoma, lung cancer, lymphoma, sarcoma, carcinoma, fibrosarcoma,
3 liposarcoma, chondrosarcoma, osteogenic sarcoma, angiosarcoma, lymphangiosarcoma,
4 synovioma, mesothelioma, meningioma, leukemia, lymphoma, leiomyosarcoma,
5 rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, papillary
6 carcinoma, cystadenocarcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular
7 carcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal carcinoma,
8 wilm's tumor, pleomorphic adenoma, liver cell papilloma, renal tubular adenoma, cystadenoma,
9 papilloma, adenoma, leiomyoma, rhabdomyoma, hemangioma, lymphangioma, osteoma,
10 chondroma, lipoma and fibroma.

1 **45.** The method of any one of claims **39** to **44**, further comprising
2 administering to the human a therapeutically effective amount of one or more additional
3 therapeutic agents.

1 **46.** The method of claim **45**, wherein the one or more additional therapeutic
2 agents is selected from the group consisting of corticosteroids, steroids, immunosuppressants,
3 Immunoglobulin G agonists, Dipeptidyl peptidase IV inhibitors, Lymphocyte function antigen-3
4 receptor antagonists, Interleukin-2 ligands, Interleukin-1 beta ligand inhibitors, IL-2 receptor
5 alpha subunit inhibitors, HGF gene stimulators, IL-6 antagonists, IL-5 antagonists, Alpha 1
6 antitrypsin stimulators, Cannabinoid receptor antagonists, Histone deacetylase inhibitors, AKT
7 protein kinase inhibitors, CD20 inhibitors, Abl tyrosine kinase inhibitors, JAK tyrosine kinase
8 inhibitors, TNF alpha ligand inhibitors, Hemoglobin modulators, TNF antagonists, proteasome
9 inhibitors, CD3 modulators, Hsp 70 family inhibitors, Immunoglobulin agonists, CD30
10 antagonists, tubulin antagonists, Sphingosine-1-phosphate receptor-1 agonists, connective tissue
11 growth factor ligand inhibitors, caspase inhibitors, adrenocorticotrophic hormone ligands, Btk
12 tyrosine kinase inhibitors, Complement C1s subcomponent inhibitors, Erythropoietin receptor
13 agonists, B-lymphocyte stimulator ligand inhibitors, Cyclin-dependent kinase-2 inhibitors, P-

14 selectin glycoprotein ligand-1 stimulators, mTOR inhibitors, Elongation factor 2 inhibitors, Cell
 15 adhesion molecule inhibitors, Factor XIII agonists, Calcineurin inhibitors, Immunoglobulin G1
 16 agonists, Inosine monophosphate dehydrogenase inhibitors, Complement C1s subcomponent
 17 inhibitors, Thymidine kinase modulators, Cytotoxic T-lymphocyte protein-4 modulators,
 18 Angiotensin II receptor antagonists, Angiotensin II receptor modulators, TNF superfamily
 19 receptor 12A antagonists, CD52 antagonists, Adenosine deaminase inhibitors, T-cell
 20 differentiation antigen CD6 inhibitors, FGF-7 ligands, dihydroorotate dehydrogenase inhibitors,
 21 Syk tyrosine kinase inhibitors, Interferon type I receptor antagonists, Interferon alpha ligand
 22 inhibitors, Macrophage migration inhibitory factor inhibitors, Integrin alpha-V/beta-6
 23 antagonists, Cysteine protease stimulators, p38 MAP kinase inhibitors, TP53 gene inhibitors,
 24 Shiga like toxin I inhibitors, Fucosyltransferase 6 stimulators, Interleukin 22 ligands, IRS1 gene
 25 inhibitors, Protein kinase C stimulators, Protein kinase C alpha inhibitors, CD74 antagonists,
 26 Immunoglobulin gamma Fc receptor IIB antagonists, T-cell antigen CD7 inhibitors, CD95
 27 antagonists, N acetylmannosamine kinase stimulators, Cardiotrophin-1 ligands, Leukocyte
 28 elastase inhibitors, CD40 ligand receptor antagonists, CD40 ligand modulators, IL-17
 29 antagonists, TLR-2 antagonists, Mannan-binding lectin serine protease-2 (MASP-2) inhibitors,
 30 Factor B inhibitors, Factor D inhibitors, C3aR modulators, C5aR2 modulators, T cell receptor
 31 antagonists, PD-1 inhibitors, PD-L1 inhibitors, TIGIT inhibitors, TIM-3 inhibitors, LAG-3
 32 inhibitors, VISTA inhibitors, STING agonists, IDO inhibitors, adenosine receptor modulators,
 33 CD39 inhibitors, CD73 inhibitors, antagonists of the chemokine receptors, especially CXCR1,
 34 CXCR2, CXCR3, CXCR4, CXCR7, CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, CCR7, CCR9,
 35 CX3CR1 and CXCR6, and combinations thereof.

1 **47.** The method of claim **45** or **46**, wherein the one or more additional
 2 therapeutic agent is selected from the group consisting of obinutuzumab, rituximab,
 3 ocrelizumab, cyclophosphamide, prednisone, hydrocortisone, hydrocortisone acetate,
 4 cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, triamcinolone
 5 acetonide, triamcinolone alcohol, mometasone, amcinonide, budesonide, desonide,
 6 fluocinonide, fluocinolone acetonide, halcinonide, betamethasone, betamethasone sodium
 7 phosphate, dexamethasone, dexamethasone sodium phosphate, fluocortolone,
 8 hydrocortisone-17-valerate, halometasone, alclometasone dipropionate, beclomethasone,

9 betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-
10 butyrate, clobetasol-17-propionate, fluocortolone caproate, fluocortolone pivalate,
11 fluprednidene acetate, hydrocortisone-17-butyrate, hydrocortisone-17-aceponate,
12 hydrocortisone-17-buteprate, ciclesonide and prednicarbate, GB-0998, immuglo, begelomab,
13 alefacept, aldesleukin, gevokizumab, daclizumab, basiliximab, inolimomab, beperminogene
14 perplasmid, sirukumab, tocilizumab, clazakizumab, mepolizumab, fingolimod, panobinostat,
15 triciribine, nilotinib, imatinib, tofacitinib, momelotinib, peficitinib, itacitinib, infliximab,
16 PEG-bHb-CO, etanercept, ixazomib, bortezomib, muromonab, orelizumab, guselkumab,
17 brentuximab vedotin, Ponesimod, KRP-203, FG-3019, emricasan, corticotropin, ibrutinib,
18 cinryze, conestat, methoxy polyethylene glycol-epoetin beta, belimumab, blisibimod,
19 atacicept, seliciclib, neihulizumab, everolimus, sirolimus, denileukin diftitox, LMB-2,
20 natalizumab, catridecacog, ciclosporin, tacrolimus, voclosporin, voclosporin, canakinumab,
21 mycophenolate, mizoribine, CE-1145, TK-DLI, abatacept, belatacept, olmesartan
22 medoxomil, sparsentan, TXA-127, BIIB-023, alemtuzumab, pentostatin, itolizumab,
23 palifermin, leflunomide, PRO-140, cenicriviroc, fostamatinib, anifrolumab, sifalimumab,
24 BAX-069, BG-00011, losmapimod, QPI-1002, ShigamAbs, TZ-101, F-652, reparixin,
25 ladarixin, PTX-9908, aganirsen, APH-703, sotrastaurin, sotrastaurin, milatuzumab, SM-101,
26 T-Guard, APG-101, DEX-M74, cardiotrophin-1, tiprelestat, ASKP-1240, BMS-986004,
27 HPH-116, KD-025, OPN-305, TOL-101, defibrotide, pomalidomide, Thymoglobulin,
28 laquinimod, remestemcel-L, Equine antithymocyte immunoglobulin, Stempeucel, LIV-
29 Gamma, Octagam 10%, t2c-001, 99mTc-sestamibi, Clairyg, ProSORBA, pomalidomide,
30 laquinimod, teplizumab, FCRx, solnatide, foralumab, ATIR-101, BPX-501, ACP-01, ALLO-
31 ASC-DFU, irbesartan + propagermanium, ApoCell, cannabidiol, RGI-2001, saratin, anti-
32 CD3 bivalent antibody-diphtheria toxin conjugate, NOX-100, LT-1951, OMS721, ALN-
33 CC5, ACH-4471, AMY-101, Acthar gel, and CD4+CD25+ regulatory T-cells, MEDI7814,
34 P32, P59, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, CCX354,
35 CCX721, CCX9588, CCX140, CCX872, CCX598, CCX6239, CCX587, CCX624, CCX282,
36 CCX025, CCX507, CCX430, CCX765, CCX758, CCX771, CCX662, CCX650, and
37 combinations thereof.